
Cumulative Index

Volume 41, Numbers 1-4, 1998

- Abdominal colposacropexy, 786
Abdominal myofascial pain, 422
Abdominal wall defects. See Ventral wall defects
Abdominal wound infection, with trial of labor after cesarean delivery, 369
Abnormal uterine bleeding
 anovulation and, 928
 with cirrhosis, 928
 differential diagnosis of, 928
 evaluation of patient with, 928
 iatrogenic causes of, 928
 luteal phase and, 928
 with malignancy, 928
 with myomas, 928
 in perimenopause, 921, 928, 976
 with pregnancy, 928
 with reproductive disorders, 928
 with thyroid disorders, 928
 treatment of, 928
Abortion, spontaneous, age-related increase in, 958
Abruptio placentae
 ambulatory management of, 527
 definition of, 527
 etiology of, 527
 grades of, 527
 hospitalization for, 527
 with hypertension in pregnancy, 533
 incidence of, 527
 outcomes with, 527
 perinatal morbidity and mortality with, 527
 with preterm premature rupture of membranes, 503
 risk factors for, 527
 signs and symptoms of, 527
 ultrasound findings with, 527
 vaginal bleeding with, 527
Abuse, history of, and chronic pelvic pain, 422
Acardiac twinning, 564
Acetylcholinesterase level, in amniotic fluid, 564
Activated protein C resistance, anticoagulation for, 545
Acupressure, for hyperemesis gravidarum, 597
Acute intermittent porphyria, chronic pelvic pain with, 422
Acute pain. See Pain, acute
Adolescent, pregnant, hypertension in, management of, 533
Adult respiratory distress syndrome, with pyelonephritis in pregnancy, 515
Agency for Health Care Policy and Research (AHCPR)
 Computerized Needs-oriented Quality Measurement Evaluation System, 348
 guidelines for healthcare, 315, 343
 internet address of, 348
 responsibilities of, 343
Aging population, demographics of, 895
Albuterol, for asthma, in pregnancy, 555
Alpha adrenergic agents
 adverse effects and side effects of, 691
 estrogen therapy in combination with, for urinary incontinence, 691
 for urinary incontinence, 691, 702
Alpha adrenergic antagonists, for voiding dysfunctions, 691
Alpha-fetoprotein level
 amniotic fluid, 564
 maternal serum
 in multiple gestation, 564
 and risk of fetal abnormalities, 564
Alprazolam
 for premenstrual syndrome, possible effectiveness of, 405
 for voiding dysfunctions, 691
Ambulatory obstetric management, 479, 481
 managed care and, 481
American Board of Obstetrics and Gynecology, American Board Certification, 307
American College of Obstetricians and Gynecologists (ACOG)
 Educational Bulletin, 343
 obstetric clinical indicators, 348
 perspective on practice guidelines, 343
 position on electronic fetal monitoring, 362
 position on obstetric ultrasound, 67
 Practice Bulletin, 343
 Practice Patterns, 343
 quality of care measures, 348
American Medical Association (AMA), perspective on practice guidelines, 343
Aminoglycosides, for pyelonephritis, 515
Amitriptyline (Elavil)
 for chronic pelvic pain, 422
 for urinary incontinence, 691
Amniocentesis
 in diagnosis of intra-amniotic infection, 503
 therapeutic, for twin-twin transfusion syndrome, 37, 105
Amnion, structure of, 810
Amniotic fluid
 acetylcholinesterase level in, 564

Page numbers listed are those on which relevant article begins.

Cumulative Index

Volume 41, Numbers 1-4, 1998

- Abdominal colposacropexy, 786
 Abdominal myofascial pain, 422
 Abdominal wall defects. See Ventral wall defects
 Abdominal wound infection, with trial of labor after cesarean delivery, 369
 Abnormal uterine bleeding
 anovulatory and, 928
 with cirrhosis, 928
 differential diagnosis of, 928
 evaluation of patient with, 928
 iatrogenic causes of, 928
 luteal phase and, 928
 with malignancy, 928
 with myomas, 928
 in perimenopause, 921, 928, 976
 with pregnancy, 928
 with reproductive disorders, 928
 with thyroid disorders, 928
 treatment of, 928
 Abortion, spontaneous, age-related increase in, 958
 Abruptio placentae
 ambulatory management of, 527
 definition of, 527
 etiology of, 527
 grades of, 527
 hospitalization for, 527
 with hypertension in pregnancy, 533
 incidence of, 527
 outcomes with, 527
 perinatal morbidity and mortality with, 527
 with preterm premature rupture of membranes, 503
 risk factors for, 527
 signs and symptoms of, 527
 ultrasound findings with, 527
 vaginal bleeding with, 527
 Abuse, history of, and chronic pelvic pain, 422
 Acardiac twinning, 564
 Acetylcholinesterase level, in amniotic fluid, 564
 Activated protein C resistance, anticoagulation for, 545
 Acupressure, for hyperemesis gravidarum, 597
 Acute intermittent porphyria, chronic pelvic pain with, 422
 Acute pain. See Pain, acute
 Adolescent, pregnant, hypertension in, management of, 533
 Adult respiratory distress syndrome, with pyelonephritis in pregnancy, 515
 Agency for Health Care Policy and Research (AHCPR)
 Computerized Needs-oriented Quality Measurement Evaluation System, 348
 guidelines for healthcare, 315, 343
 internet address of, 348
 responsibilities of, 343
 Aging population, demographics of, 895
 Albuterol, for asthma, in pregnancy, 555
 Alpha adrenergic agents
 adverse effects and side effects of, 691
 estrogen therapy in combination with, for urinary incontinence, 691
 for urinary incontinence, 691, 702
 Alpha adrenergic antagonists, for voiding dysfunctions, 691
 Alpha-fetoprotein level
 amniotic fluid, 564
 maternal serum
 in multiple gestation, 564
 and risk of fetal abnormalities, 564
 Alprazolam
 for premenstrual syndrome, possible effectiveness of, 405
 for voiding dysfunctions, 691
 Ambulatory obstetric management, 479, 481
 managed care and, 481
 American Board of Obstetrics and Gynecology, American Board Certification, 307
 American College of Obstetricians and Gynecologists (ACOG)
 Educational Bulletin, 343
 obstetric clinical indicators, 348
 perspective on practice guidelines, 343
 position on electronic fetal monitoring, 362
 position on obstetric ultrasound, 67
 Practice Bulletin, 343
 Practice Patterns, 343
 quality of care measures, 348
 American Medical Association (AMA), perspective on practice guidelines, 343
 Aminoglycosides, for pyelonephritis, 515
 Amitriptyline (Elavil)
 for chronic pelvic pain, 422
 for urinary incontinence, 691
 Amniocentesis
 in diagnosis of intra-amniotic infection, 503
 therapeutic, for twin-twin transfusion syndrome, 37, 105
 Amnion, structure of, 810
 Amniotic fluid
 acetylcholinesterase level in, 564

Page numbers listed are those on which relevant article begins.

- alpha-fetoprotein level in, 564
- assessment
 - with preterm premature rupture of membranes, 832, 849, 870
 - in diagnosis of intrauterine infection, 849
 - with prolonged premature rupture of membranes, 817
- automated WBC count, in diagnosis of intrauterine infection with PPROM, 849
- catalase, and intrauterine infection with PPROM, 849
- cytokines, and intrauterine infection with PPROM, 849
- ferning, with rupture of membranes, 503
- glucose concentration, in diagnosis of intrauterine infection with PPROM, 849
- Gram stain, in diagnosis of intrauterine infection with PPROM, 849
- interleukin-1 β , and intrauterine infection with PPROM, 849
- interleukin-6, and intrauterine infection with PPROM, 849
- leukocyte esterase, and intrauterine infection with PPROM, 849
- nitrazine test for, with rupture of membranes, 503
- pooling in posterior vaginal fornix, with rupture of membranes, 503
- testing, in diagnosis of intra-amniotic infection, 503
- volume, and intrauterine infection with PPROM, 849
- Amniotic fluid index
 - frequency of determinations of, 647
 - as marker of placental function, 647
- Amoxicillin, for preterm premature rupture of membranes, dosage and administration of, 461
- Ampicillin
 - with gentamicin and clindamycin, for preterm premature rupture of membranes, 864
 - for preterm premature rupture of membranes, 461, 864, 870
 - for pyelonephritis, 515
- Ampicillin-sulbactam, for preterm premature rupture of membranes, 864
- Analgesics, oral, for chronic pelvic pain, 422
- Anemia
 - in multiple gestation, 564
 - with twin gestation, 85
- Anencephaly, 393
- Aneuploidy
 - fetal, in multiple gestation
 - detection of, 564
 - risk of, 564
 - maternal age-related increase in, 958
- Angiotensin-converting enzyme inhibitors, in pregnancy, adverse effects of, 533
- Antenatal testing. *See also* Fetal assessment
 - in ambulatory setting, 481
 - costs of, 481
 - variation in, by geographic region, 481
- Antepartum testing. *See also* Fetal assessment
 - Doppler velocimetry in, 647
 - frequency of, 647
 - historical perspective on, 647
 - indications for, 647
 - initiation of, 647
- Antibiotic therapy
 - for chorioamnionitis, 503
 - for chronic pelvic pain, 422
 - for preterm premature rupture of membranes, 461, 503, 832, 864, 870
 - and gestational age-dependent morbidity, 461, 827
 - maternal outcome with, 461, 827
 - NICHD-MFMU multicenter trial of, 461, 870
 - and perinatal infectious morbidity, 461, 827
 - and perinatal mortality, 461, 827, 870
 - pregnancy prolongation with, 461, 870
 - prospective trials of, 461, 864, 870
 - rationale for, 864
 - recommendations for, 864
 - regimen for, 461
- for pyelonephritis, 515, 744
- intramuscular, 515
- intravenous, 515
- oral, 515
- in pregnancy, 744
- for urinary tract infections, 744
- Anticholinergic agents
 - adverse effects and side effects of, 691
 - antispasmodic, for urinary incontinence, 691
 - for urinary incontinence, 691
- Anticoagulation, 545
 - for activated protein C resistance, 545
 - agents for, 545
 - for antiphospholipid antibody syndrome, 545
 - for antithrombin deficiency, 545
 - for coagulation disorders associated with thrombosis, 545
 - indications for, in pregnancy and puerperium, 545
 - inpatient management of, 545
 - prophylactic, 545
 - for protein C deficiency, 545
 - for protein S deficiency, 545
 - therapeutic
 - dosage and administration of, 545
 - intrapartum management and, 545
 - for venous thromboembolism, 545
- Anti-D antibodies (Rhogam), for idiopathic thrombocytopenic purpura in pregnancy, 436
- Antiemetics
 - for hyperemesis gravidarum, 597
 - for nausea and vomiting in pregnancy, 597
- Antihistamines, for asthma, in pregnancy, 555
- Antihypertensive therapy
 - effects on urinary incontinence, 663
 - in pregnancy, studies of, 533
- Anti-inflammatory agents, for asthma, in pregnancy, 555
- Antiphospholipid antibody syndrome, anticoagulation for, 545
- Antithrombin, deficiency, anticoagulation for, 545
- Anxiety, maternal
 - during antepartum care in high-risk pregnancy, 626
 - postpartum, early postpartum discharge and, 611
- Anxiolytics, for premenstrual syndrome, possible effectiveness of, 405
- ARDS. *See* Adult respiratory distress syndrome
- ART. *See* Assisted reproductive technology
- Aspirin, for anticoagulation, in pregnancy, 545
- Assisted reproductive technology (ART)
 - monozygotic twinning with, 127
 - multifetal gestation and, 47, 57, 127, 564
 - in older women, 940
 - success rates, in older women, 940

- twin gestation and, 3
- Asthma
 - airway hyperresponsiveness in, 555
 - definition of, 555
 - effect of pregnancy on, 555
 - effects on pregnancy, 555
 - exacerbation of
 - fetal effects of, 555
 - management during pregnancy, 555
 - signs and symptoms of, 555
 - stimuli for, 555
 - inflammation in, 555
 - mild
 - definition of, 555
 - management during pregnancy, 555
 - moderate
 - definition of, 555
 - management during pregnancy, 555
 - mortality with, 555
 - pathophysiology of, 555
 - in pregnancy
 - fetal assessment with, 555
 - fetal complications of, 555
 - hospitalization for, 555
 - management of, 555
 - maternal assessment with, 555
 - maternal complications of, 555
 - morbidity and mortality with, 555
 - outcomes with, 555
 - pharmacologic therapy for, 555
 - rapid progression of, risk factors for, 555
 - severity of, 555
 - prevalence of, 555
 - severe
 - definition of, 555
 - management during pregnancy, 555
 - triggers, 555
 - removal of, in outpatient management during pregnancy, 555
- Asymptomatic bacteriuria
 - in children, 744
 - in chronic illness, 744
 - definition of, 515, 744
 - in diabetes mellitus, 744
 - in elderly women, 744
 - epidemiology of, 744
 - in full-term infants, 744
 - in pregnancy, 744
 - management, incremental cost-effectiveness of, 296
 - prevalence of, 744
 - progression to clinical urinary tract infection, 744
 - and pyelonephritis, 515
- Ataxia, assessment for, in patient with urinary incontinence, 663
- Ataxia telangiectasia, 172
- Ativan. See Lorazepam
- Atropine, for urinary incontinence, 691
- Baclofen, for voiding dysfunctions, 691
- Bacteremia, and pyelonephritis, 515, 744
- Bacterial vaginosis, and preterm delivery, 810
- Bacteriuria. See also Asymptomatic bacteriuria
 - after cystourethroscopy, 764
 - in pregnancy, 744
 - signs and symptoms of, 744
- Baden defect analyzer, 777
- Bayes' theorem, 267
- Beck Depression Inventory, 422
- Beclomethasone, for asthma, in pregnancy, 555
- Bed rest
 - in high-risk pregnancy
 - adherence to, 626
 - boredom with, reduction of, 626
 - checklist for, 626
 - coping with, 626
 - father's perspective on, 626
 - home versus hospital, 626
 - patient information about, 626
 - prescription of, practices in, 481
 - recommendations for research on, 626
 - resource books on, 626
 - stressors related to, 626
 - support groups and networks for, 626
 - in multiple gestation, 564
 - for placenta previa, 527
 - for preterm labor and threatened preterm delivery, 491
 - with preterm premature rupture of membranes, 870
 - and prevention of preterm delivery in twin gestation, 13
- Behavior therapy, for urinary incontinence, 702
- Bendectin, for hyperemesis gravidarum, 597
- Bentyl. See Dicyclomine hydrochloride
- Benzodiazepines, for voiding dysfunctions, 691
- Beta-blockers, in pregnancy, 533
- Betamimetic therapy, and prevention of preterm delivery in twin gestation, 13
- Bethanechol chloride, for urinary incontinence
 - adverse effects and side effects of, 691
 - dosage and administration of, 691
 - mechanism of action, 691
 - precautions with, 691
- Bias. See also Recall bias
 - empirical evidence of, 245
 - in historical comparisons, 245
 - nonrandomized comparisons and, 245
 - in observational studies, 235
 - prevention of
 - in randomized controlled trials, 245
 - study design and, 307
 - in randomized controlled trials, prevention of, 245
- Biofeedback, for pelvic floor muscle strengthening, 702
- Biophysical profile
 - advantages and disadvantages of, 647
 - in diagnosis of intra-amniotic infection, 503
 - frequency of, 647
 - and intrauterine infection with PPROM, 849, 870
 - modified, 647
 - frequency of, 647
 - in multiple gestation, 564
 - principles and rationale for, 647
- Birth certificates, data from, 3
- Birth defects, prenatally diagnosed
 - management options for, 393
 - prophylactic cesarean delivery for, 393
- Birth weight
 - discordancy, and neonatal mortality with multiple gestation, 57
 - of multiples, characterization, 57

- of twins, relationship to intrauterine growth and gestational age, 57, 115
- Bishop score, 606
- Bladder
 - anatomy of, normal, 755
 - capacity, in females, 672
 - catheterization, postoperative
 - catheters for, 735
 - discontinuation of, 735
 - infectious complications of, 735
 - survey of urogynecologists' programs for, 735
 - techniques, 735
 - contractility, agents that decrease, 691
 - cystitis cystica, 764
 - cystitis glandularis, 764
 - diverticula, 764
 - drainage, postoperative, 735
 - fistulas, 764
 - functions of, normal, 755
 - injury and repair of, 755
 - interstitial cystitis, 764
 - neurophysiology of, 691
 - pathology of, on cystourethroscopy, 764
 - pseudomembranous trigonitis, 764
 - trabeculation, 764
 - transitional cell carcinoma, 764
- Bladder drill, 702
- Bladder neck support prosthesis, 702
- Bladder pressure, measurement of, 672
- Bleeding. *See also* Dysfunctional uterine bleeding
 - abnormal uterine, in perimenopause, 921, 976
 - with idiopathic thrombocytopenic purpura, 436
 - neonatal, with ITP in pregnancy, 436
 - vaginal, in second half of pregnancy, 527
- Blinding
 - assessment of, 307
 - definition of, 307
 - in randomization, 245, 307
- Blood glucose, in pregnant diabetic
 - postprandial levels as predictor of fetal macrosomia, 584
 - self-monitoring of, 584
 - target levels for, 584
- Boredom, maternal, during antepartum care in high-risk pregnancy, 626
- Bowel dysmotility disorders, chronic pelvic pain and, 422
 - medical therapy for, 422
- BRCA1 and BRCA2 genes
 - direct mutation analysis for, 141
 - founder mutations, 157, 200
 - mutations, 157
 - clinical implications, 157, 172, 200
 - familial breast-ovarian cancer linked to, 157, 172, 200, 215
 - genetic testing for, 141, 157
 - population screening for, 141, 200
- Breast cancer
 - familial, 157, 172
 - epidemiology, 200
 - prophylactic surgery and, 215
 - risk assessment, genetic testing for, 141
 - risk reduction, 200
 - history of, estrogen replacement therapy and, 966
 - postmenopausal hormone replacement therapy and, 966
 - screening for, 200
 - U.S. Preventive Services Task Force recommendations on, 332
- Breast-feeding, early postpartum discharge and, 611
- Breast stimulation, and uterine contraction, 606
- Breech presentation, and trial of labor after cesarean delivery, 369
- Bromocriptine, for premenstrual syndrome, ineffectiveness of, 405
- Bronchial asthma. *See* Asthma
- Bronchodilators, for asthma, in pregnancy, 555
- Bupivacaine (Marcaine)
 - for epidural analgesia, concentration of, effects on malposition, instrument use, vaginal delivery, and cesarean delivery, 449
 - for trigger point treatment, 422
- Burch urethropexy, 712, 786
 - laparoscopic, 712
- Buspirone, for premenstrual syndrome, possible effectiveness of, 405
- Calcium channel blockers
 - adverse effects and side effects of, 691
 - mechanism of action of, 533
 - for urinary incontinence, 691
- Cancer
 - general population screening for, 141, 200
 - high-risk population screening for, 200
 - women with, genetic testing of, 141
- Cancer risk
 - assessment, genetic testing for, 141
 - family history and, 141, 200, 215
 - genetic counseling about, 141
 - ovulation induction in older women and, 940
 - p53 tumor suppressor gene and, 172
- Cardiovascular disease, in perimenopause, 966, 976
- Cardura. *See* Doxazosin mesylate
- Case-control studies
 - advantages and disadvantages of, 235
 - analysis of, 235
 - ascertainment of exposure in, 235
 - confounders in, 307
 - evaluation of, 235, 307
 - for evaluation of multiple exposures, 235
 - measure of association in, 235
 - method for, 235
 - principles and rationale for, 235
 - problems with, 235
 - recall bias in, 307
 - selection of controls for, 235
- Case reports, 235
- Case series, 235
- Catalase, amniotic fluid, and intrauterine infection with PPROM, 849
- Catheter(s). *See* Indwelling transurethral catheter; Suprapubic catheter
- CA 125 tumor-associated antigen
 - and cancer risk, 200, 215
 - screening, evaluation of, study design for, 267
- Causality
 - determination of, use of epidemiologic data for, 235
 - evaluation of, 235, 307
- Causation

- criteria for, 235, 307
- evaluation of, 235, 307
- Cefazolin, for pyelonephritis, 515
- Ceftriaxone, for pyelonephritis, 515
- Center For the Study of Multiple Birth, 85
- Cephalosporins
 - for preterm premature rupture of membranes, dosage and administration of, 461
 - for pyelonephritis, 515
- Cerclage. See Cervix, cerclage
- Cervical cancer, p53 tumor suppressor gene and, 172
- Cervical cerclage
 - emergent, 37
 - in multiple gestation, 564
 - and preterm premature rupture of membranes, 503, 870
 - and prevention of preterm delivery in twin gestation, 13, 37
- Cervical dilation, digital assessment of, 491
- Cervical ripening, 606
 - definition of, 606
 - and induction of labor, 606
 - in management of premature rupture of membranes in term patients, 883
 - mechanical dilators for, 606
 - by membrane stripping, 606
 - methods for
 - nonpharmacologic, 606
 - pharmacologic, 606
 - mifepristone for, 606
 - monitoring with, 606
 - outpatient techniques for, 606
 - prostaglandins for, 606
 - relaxin for, 606
 - safety considerations in, 606
 - treatment setting for, 606
- Cervical stenosis, chronic pelvic pain with, 422
- Cervix
 - funneling, and preterm labor/delivery, 95
 - incompetence, and pregnancy loss in multiple gestations, 37
 - length
 - measurements, in multifetal gestation, 95
 - and risk of preterm labor, 491
 - status, assessment in multifetal gestation, 95
 - transvaginal sonographic evaluation of, in pregnancy, 491
 - ultrasound evaluation of, and digital evaluation, comparison, 95
- Cesarean delivery
 - antibiotic therapy for preterm premature rupture of membranes and, 461
 - for dystocia, effects of epidural analgesia on, 449
 - early postpartum discharge after, 611
 - follow-up care with, 611
 - guidelines for, 611
 - maternal and neonatal outcomes with, 611
 - safety of, 611
 - economic costs of, 393
 - elective repeat, 369
 - decision to proceed with, factors affecting, 369
 - epidural analgesia for, 449
 - hospitalization after, recommended length of stay, 611
 - indications for, 369
 - infectious complications of, 611
 - maternal morbidity with, 393
 - maternal mortality after, 611
 - medicolegal considerations with, 393
 - for multiple pregnancy, and maternal mortality, 79
 - postoperative pain after, randomized clinical trial of, sample size for, 257
 - prophylactic
 - maternofetal conflict and, 393
 - for neural tube defects, 393
 - for prenatally diagnosed malformations, 393
 - risks of, 393
 - for ventral wall defects, 393
 - rate, 393
 - effect of epidural analgesia on, 449
 - effect of trial of labor on, 348
 - reduction of, 369
 - social influence model of intervention and, 348
 - in United States, 369
 - repeat, complications of, 369
 - and risk of placenta previa in subsequent pregnancy, 527
 - risks of, 393
 - trial of labor after. See Trial of labor, after cesarean delivery
 - for triplets and higher order multiples, 25
 - for twins, 31
 - two or more previous, and uterine rupture with trial of labor, 369
 - vaginal birth after. See Vaginal birth after cesarean delivery
- CFTR gene, direct mutation analysis for, 141
- Chemoprophylaxis, U.S. Preventive Services Task Force recommendations on, 332
- Childbirth. See also Delivery
 - healthcare interventions in, systematic reviews of, 315
 - in hospital, historical perspective on, 611
- Chlamydia, urinary tract infection caused by, 744
- Chlorpheniramine, for asthma, in pregnancy, 555
- Chorioamnionitis
 - antibiotic therapy for, 503
 - epidural analgesia and, 449
 - management of, 503
 - and preterm delivery, 810
 - with preterm premature rupture of membranes, 503, 827, 832, 849
 - diagnostic criteria for, 503
 - tests for, 503
 - preterm premature rupture of membranes and, 461, 864, 870
- Chorion, structure of, 810
- Chromosomal abnormalities
 - in offspring, maternal age-related incidence of, 898, 940, 958
 - in twin gestations, 564
- Chronic pain. See Chronic pelvic pain; Pain, chronic
- Chronic pelvic pain
 - abuse history with, 422
 - biopsychosocial model of, 422
 - and bowel dysmotility disorders, 422
 - medical therapy for, 422
 - cognitive-behavioral therapy for, 422
 - cyclic, 422
 - medical management of, 422

- definition of, 422
- diagnosis of, 422
- with endometriosis, 422
- epidemiology of, 422
- etiology of, 422
- evaluation of
 - laparoscopy in, 422
 - standardized, 422
- evidence-based management of, 422
- gynecologic causes of, 422
- and healthcare utilization, 422
- management of, 422
 - multidisciplinary approach to, 422
- medical therapy for, 422
- musculoskeletal factors in, 422
 - medical management of, 422
- nongynecologic causes of, 422
- with pelvic adhesions, 422
- physical assessment with, 422
- population demographics with, 422
- prevalence of, 422
- psychosocial considerations with, 422
- socioenvironmental considerations with, 422
- surgical treatment of, 422
- trigger points and, 422
 - diagnosis of, 422
- unusual diagnoses associated with, 422
- urologic factors in, 422
- Chronic urethral syndrome, 422
- Cirrhosis, abnormal uterine bleeding with, 928
- A Classified Bibliography of Controlled Trials in Perinatal Medicine 315, 1940-1984
- Clinically meaningful effect, 257
- Clinical trials, randomized. *See also* Randomized controlled trials (RCTs)
 - Cochrane's thoughts on, 315
 - in obstetrics, Cochrane's thoughts on, 315
 - perinatal, register of, 315
 - principles and rationale for, 315
- Clomiphene citrate, for ovarian stimulation, 127
- Clomipramine, for premenstrual syndrome, effectiveness of, 405
- Coagulation
 - disorders, associated with thrombosis, anticoagulation for, 545
 - physiologic changes in, during pregnancy, 545
- Cochrane, Archie
 - challenge to obstetrics re randomized clinical trials, 315
 - "Effectiveness and Efficiency," 315
- Cochrane Collaboration
 - development of, 315
 - organization of, 315
- Cochrane Controlled Trials Register (CCTR), 315
- Cochrane Database of Systematic Reviews (CDSR), 315
- Cochrane Library, 315
- Cognitive-behavioral therapy, for premenstrual syndrome, possible effectiveness of, 405
- Cohort studies
 - advantages and disadvantages of, 235
 - concurrent versus nonconcurrent, 235
 - for determining prognostic factors, 235
 - evaluation of, 307
 - in literature, evaluation of, 235, 307
 - measure of association for, 235
 - method for, 235
 - prospective, 235
 - purposes of, 235
 - retrospective, 235
- Collaborative Review Groups (CRGs), 315
- Collagen, in amnion and chorion, and premature rupture of membranes, 810
- Collagenase
 - bacterial, and premature rupture of membranes, 810
 - and premature rupture of membranes, 810
 - type V, in amniotic fluid, 810
- Colorectal cancer
 - familial, epidemiology, 200
 - population screening for, 200
- Colposacropexy, abdominal, 786
- Confidentiality
 - of genetic testing for cancer risk assessment, 141, 157
 - and telephone contacts, 640
- Confounders, in case-control studies, 307
- Congenital anomalies/malformations
 - antenatal diagnosis, 67
 - in infants of diabetic mothers, 584
 - management, 67
 - in multiple gestation, 564
 - and neonatal mortality with multiple gestation, 57
 - in oligohydramnios tetrad, 817
 - prenatally diagnosed
 - management options for, 393
 - prophylactic cesarean delivery for, 393
 - with preterm premature rupture of membranes, 503, 827, 870
- Consolidated Standards of Reporting Trials (CONSORT), 245
- Constipation, medical therapy for, 422
- Continuous quality improvement (CQI), 348
- Contraception. *See also* Oral contraceptives and smoking, 958
 - and urinary tract infections, 744
 - for women older than 35, 951, 958, 976
 - barrier methods, 951
 - IUD for, 951
 - methods of, 951
 - oral contraceptives for, 951
 - periodic abstinence as, 951
 - types used, 951
- Contraction stress test
 - contraindications to, 647
 - frequency of, 647
 - limitations of, 647
 - in multiple gestation, 564
 - principles and rationale for, 647
- Cordocentesis, for determination of fetal platelet count, 436
- Corticosteroids
 - antenatal administration of, value of, systematic review of, 315
 - for asthma, in pregnancy, 555
 - for hyperemesis gravidarum, 597
 - for preterm premature rupture of membranes, 461, 503, 564, 832, 842, 870
 - potential interaction with tocolysis, 842
- Cost analysis, 296. *See also* Sensitivity analysis
 - evaluation of, 296
 - factors affecting, 296
 - in healthcare, difficulties of, 296

- individual patient perspective for, 296
- methods of, 296
- results of, evaluation of, 296
- societal perspective for, 296
- types of, 296
- Cost-benefit analysis, 296
 - discounting in, 296
 - in medicine, problems with, 296
 - method for, 296
 - and sensitivity analysis, 296
- Cost-effectiveness analysis, 296. See also Cost analysis; Incremental cost-effectiveness
- Cost minimization analysis, 296. See also Cost analysis
- Cost-utility analysis, 296
- Counseling, U.S. Preventive Services Task Force recommendations on, 332
- CPEP trial, sample size in, 257
- Cranial dysraphism, 393
- C-reactive protein
 - assay, in diagnosis of intra-amniotic infection, 503
 - maternal, in diagnosis of intrauterine infection with PPROM, 849
- Cromolyn sodium, for asthma, in pregnancy, 555
- Cross products ratio, calculation of odds ratio using, 235
- Cross-sectional studies, 235
 - advantages and disadvantages of, 235
 - design of, 235
 - evaluation of, 307
- CST. See Contraction stress test
- Cystitis
 - acute
 - definition of, 744
 - recurrence rate, 744
 - treatment of, 744
 - definition of, 744
 - hematuria with, 744
 - interstitial, chronic pelvic pain with, 422
 - recurrent, chronic pelvic pain with, 422
 - signs and symptoms of, 744
- Cystitis cystica, 764
- Cystitis glandularis, 764
- Cystocele
 - displacement (paravaginal), 777
 - distention (central), 777
 - identification of, 663
 - postoperative development of, 719
 - surgical management of, 777, 786
- Cystometry
 - detrusor hyperreflexia on, 672
 - detrusor instability on, 672
 - multichannel
 - and single-channel, comparison of, 672
 - subtracted, 672
 - in office setting, 672
 - procedure for, 672
 - single-channel, 672
 - and multichannel, comparison of, 672
 - in urodynamic testing, 672
 - variables in, 672
- Cystoscopy
 - intraoperative, 755
 - preoperative, 755
- Cystourethroscopy, 764
 - bacteriuria after, 764
 - bladder pathology seen on, 764
 - complications of, 764
 - contraindications to, 764
 - cystoscope sheath for, 764
 - distending media for, 764
 - endoscope for, 764
 - indications for, 764
 - instrumentation for, 764
 - light source for, 764
 - technique, 764
 - telescope lenses for, 764
 - training in, 764
 - ureteral abnormalities seen on, 764
 - urethral pathology seen on, 764
 - urethroscope sheath for, 764
 - working sheath for, 764
- Cytokines
 - amniotic fluid, and intrauterine infection with PPROM, 849
 - maternal urinary, and intrauterine infection with PPROM, 849
- Dalteparin
 - anticoagulation therapy with, 545
 - dosage and administration of, in pregnancy, 545
- Danazol
 - adverse effects and side effects of, 928
 - ovulation suppression by, for premenstrual syndrome, effectiveness of, 405
 - for women with dysfunctional uterine bleeding, 928
- Danbury Hospital (Danbury CT), quality improvement program of, 348
- Dantrium. See Dantrolene
- Dantrolene, for voiding dysfunctions, 691
- Death. See Maternal mortality; Perinatal morbidity and mortality
- Decision analysis, 282
 - acceptance of, 282
 - advantages of, 282
 - applications of, 282
 - clinical, 282
 - components of, 282
 - health policy, 282
 - limitations of, 282
 - medical, types of, 282
 - principles and rationale for, 282
 - software for, 282
 - suggested further reading on, 282
 - technique of, 282
 - use of, 282
 - utilities (values) in, 282
 - validity of, assessment of, 282
- Decision problems in clinical medicine, difficult, taxonomy of, 282
- Deep tendon reflexes, assessment of, in patient with urinary incontinence, 663
- Deep venous thrombosis
 - diagnosis of, 545
 - treatment of, 545
- Dehydration, neonatal, and early postpartum discharge, 611
- Delivery
 - cesarean. See Cesarean delivery
 - indications for, with mild maternal hypertension, 533
 - instrument use in, effects of epidural analgesia on, 449

- length of hospital stay after, 611. See also Early postpartum discharge
- and placenta previa, 481
- preterm
- history-taking and, 491
 - with hypertension in pregnancy, 533
 - management of, 481
 - with preterm premature rupture of membranes, 503, 827
 - pyelonephritis and, 515
 - risk factors for, 491
 - risk of, fetal fibronectin test as indicator of, 481, 491
 - and risk of preterm delivery in subsequent pregnancy, 491
 - with preterm premature rupture of membranes, 503, 827, 842
- vaginal. See also Vaginal birth after cesarean delivery
- early postpartum discharge after, maternal and neonatal outcomes with, 611
 - effects of epidural analgesia on, 449
 - hospitalization after, recommended length of stay, 611
- Delivery route
- in management of ITP in pregnancy, 436
 - for triplets and higher order multiples, 25
 - for twins, 31
- δ (effect size), 257
- Depomedroxyprogesterone (Depo-Provera)
- for ovarian cycle suppression, with chronic pelvic pain, 422
 - ovulation suppression by, for premenstrual syndrome, 405
- Depression
- with hyperemesis gravidarum, 597
 - maternal
 - during antepartum care in high-risk pregnancy, 626
 - postpartum, early postpartum discharge and, 611
 - and pelvic floor disorders, 657
 - in perimenopause, 921, 966, 976
 - and urinary incontinence, 663
- Descriptive studies, 235
- Designing Clinical Research (Hulley and Cummings), 257
- Detrusor areflexia, 691
- Detrusor hyperreflexia
- on cystometry, 672
 - definition of, 691
- Detrusor instability
- on cystometry, 672
 - definition of, 691
 - preoperative diagnosis of, 777
- Detrusor sphincter dyssynergia, 691
- Diabetes mellitus
- asymptomatic bacteriuria in, 744
 - classification of, 584
 - gestational. See Gestational diabetes
 - insulin-dependent (type 1)
 - clinical characteristics of, 584
 - epidemiology of, 584
 - noninsulin-dependent (type 2)
 - clinical characteristics of, 584
 - epidemiology of, 584
 - preconception care and, 584
 - in pregnancy. See also Gestational diabetes
 - ambulatory management of, 584
 - classification of, 584
 - congenital malformations related to, 584
 - diet therapy for, 584
 - exercise and, 584
 - fetal assessment with, 584
 - glycemic control in, 584
 - glycosylated hemoglobin and, 584
 - insulin therapy for, 584
 - management of, historical perspective on, 584
 - metabolic status with, monitoring, 584
 - outcomes with, 584
 - pregnancy complications with, 584
 - self-monitoring of blood glucose in, 584
- Diagnostic indices, calculation of, 267
- Diagnostic tests
- evaluation of, study design for, 267
 - negative predictive value of, calculation of, 267
 - positive predictive value of, calculation of, 267
 - and screening tests, comparison of, 267
 - sensitivity of, 267
 - specificity of, 267
 - study of
 - evaluation of, 267
 - methodology of, evaluation of, 267
 - results of
 - evaluation of, 267
 - and patient care, 267
 - reproducibility of, 267
- Diazepam, for voiding dysfunctions, 691
- Dicyclomine hydrochloride, for urinary incontinence, 691
- Diet, for pregnant diabetics, 584
- Dietary modification, for premenstrual syndrome, possible effectiveness of, 405
- Dilation and curettage, for women with dysfunctional uterine bleeding, 928
- Discounting, in cost-benefit analysis, 296
- Ditropan. See Oxybutynin chloride
- Diuretic therapy, in pregnancy, adverse effects of, 533
- Documentation, of telephone contacts, 640
- Doppler velocimetry, in antepartum testing, 647
- Doxazosin mesylate, for voiding dysfunctions, 691
- Doxepin (Sinequan)
- for chronic pelvic pain, 422
 - for urinary incontinence, 691
- Doxylamine, for hyperemesis gravidarum, 597
- Dysfunctional uterine bleeding (DUB). See also Abnormal uterine bleeding
- in perimenopause, 928
 - treatment of, multicenter clinical trial of, 257
- Dysmenorrhea, and chronic pelvic pain, 422
- Dystocia, shoulder, 332
- Early postpartum discharge, 611
- cost-effectiveness of, 611
 - definition of, 611
 - follow-up, for infants of low-income women, 611
 - historical perspective on, 611
 - insurer-mandated, 611
 - legal considerations with, 611
 - legislative regulation of
 - federal, 611
 - by states, 611
 - literature on, critical review of, 611

- maternal and newborn outcomes with, 611
- maternal issues after, 611
- newborn after
 - follow-up examination of, 611
 - genetic screening tests for, 611
 - hyperbilirubinemia in, 611
 - problems of, 611
 - rehospitalization rates for, 611
 - nurses' in-home visits after, 611
- Eclampsia, definition of, 533
- Ecologic studies, 235
 - design of, 235
 - use of, 235
- Ectopic pregnancy, medical management of, 382
 - laparoscopic salpingostomy in, 382
 - local methotrexate in, 382
 - methods of, 382
 - systemic methotrexate in, 382
- Edema, definition of, 533
- Effective Care in Pregnancy and Childbirth (ECPC), 315
- Effective Newborn Care, 315
- Effect size (δ), 257
- Elavil. *See* Amitriptyline hydrochloride
- Electrical stimulation, for pelvic floor muscle strengthening, 702
- Electrocardiography, fetal, 647
- Electromyography, in urogynecology
 - indications for, 672
 - principles and rationale for, 672
- Electronic fetal monitoring (EFM)
 - efficacy of, meta-analysis of, 275, 362
 - U.S. Preventive Services Task Force recommendations on, 332
- Emeprium bromide, for urinary incontinence, 691
- Emeprium carragenate, for urinary incontinence, 691
- Encephalocele, 393
- Endocrine changes, in perimenopause, 913, 921, 976
- Endometrial ablation, in treatment of dysfunctional uterine bleeding, 928
- Endometrial biopsy, in patient with abnormal uterine bleeding, 928
- Endometrial cancer
 - dysfunctional uterine bleeding with, 928
 - estrogen replacement therapy and, 966
 - estrogen status and, 167
 - familial, 167
 - epidemiology, 200
 - risk reduction, 200
 - genetics, studies of, 167
 - incidence, 167
 - mortality, 167
 - population screening for, 200
 - p53 tumor suppressor gene and, 172
 - risk factors for, 167, 200, 928
- Endometrial hyperplasia and carcinogenesis, 928
 - dysfunctional uterine bleeding with, 928
 - perimenopausal, hormone replacement therapy and, 966
- Endometriosis, chronic pelvic pain with, 422
- Endometritis, postpartum, with preterm premature rupture of membranes, 503, 832
- Endoscopic laser surgery, for twin-twin transfusion syndrome, 37, 105
- Enoxaparin
 - for anticoagulation therapy, 545
 - dosage and administration of, in pregnancy, 545
- Enteral nutrition, in hyperemesis gravidarum, 597
- Enterocoele
 - identification of, 663
 - intraoperative, in hysterectomy, 786
 - and rectocele, differentiation of, 663
 - surgical management of, 786
- Enzymes, collagenolytic
 - bacterial, and premature rupture of membranes, 810
 - and premature rupture of membranes, 810
- Ephedrine
 - in management of urinary incontinence, 702
 - for urinary incontinence, 691
- Epidermal growth factor, and age-related ovarian changes, 898
- Epidural analgesia, for labor
 - advantages of, 449
 - effect on cesarean delivery rate, 449
 - prospective trials of
 - comparing two epidural techniques, 449
 - randomizing to epidural versus nonepidural, 449
 - retrospective studies of, 449
 - comparing epidural versus nonepidural groups, 449
 - using historical control groups, 449
 - and intrapartum maternal fever, 449
 - timing of epidural placement, and risk of cesarean delivery, 449
- Epi-Info 6.0, 257
- Epsilon-aminocaproic acid, for women with dysfunctional uterine bleeding, 928
- Erythrocyte sedimentation rate, in diagnosis of intrauterine infection with PPROM, 849
- Erythromycin, for preterm premature rupture of membranes, 461, 864, 870
- Escherichia coli
 - pyelonephritis caused by, 515, 744
 - urinary tract infection caused by, 744
- Estradiol
 - levels, age-related changes in, 913
 - ovulation suppression by, for premenstrual syndrome, effectiveness of, 405
 - for urinary incontinence, 691
- Estriol
 - maternal salivary levels of, and risk of preterm delivery, 491
 - for urinary incontinence, 691
- Estrogen replacement therapy
 - contraindications to, 966
 - and endometrial cancer, 966
 - and history of breast cancer, 966
 - and hypertriglyceridemia, 966
 - for perimenopausal woman, 976
 - risk/benefit assessment for, 966
- Estrogen therapy
 - benefits of, 691
 - in combination with alpha adrenergic agonists, for urinary incontinence, 691
 - effects on incidence of UTIs, 744
 - for urinary incontinence, 691, 702
- Evening primrose oil (EPO), for premenstrual syndrome, ineffectiveness of, 405
- Evidence
 - levels of, 307, 332

- review and rating, by U.S. Preventive Services Task Force, 307, 332
- Evidence-based healthcare quality management in OB/GYN, 348
- Evidence-based literature evaluation, on trial of labor after cesarean delivery, 369
- Evidence-based management, of chronic pelvic pain, 422
- Evidence-based medicine
 - principles of, in purchasing and management of healthcare resources, 348
 - U.S. Preventive Services Task Force and, 332
- Evidence-based OB/GYN, need for, DR1
- Evidence-based practice guidelines, 343
- Exencephaly, 393
- Exercise
 - aerobic, for premenstrual syndrome, possible effectiveness of, 405
 - and pregnant diabetics, 584
- Familial adenomatous polyposis, 172, 200
- Family history, and cancer risk, 141, 200, 215
- Fatigue, maternal postpartum, early postpartum discharge and, 611
- Fee for service system, quality of care in, 481
- Fenretinide (4-HPR), and cancer risk reduction, 200
- Fern test, of amniotic fluid, with rupture of membranes, 503
- Fertility
 - age-related changes in, 898, 940, 958
 - in perimenopause, 921, 958, 976
 - reproductive aging and, 913, 940
- Fertility drugs, and cancer risk, 200
- Fetal anomalies/malformations
 - causes of, 564
 - hyperemesis gravidarum with, 597
 - in oligohydramnios tetrad, 817
 - prenatally diagnosed
 - management options for, 393
 - prophylactic cesarean delivery for, 393
 - with preterm premature rupture of membranes, 503, 827, 870
- Fetal assessment
 - with diabetes in pregnancy, 584
 - historical perspective on, 647
 - with intrauterine infection, 849
 - with maternal hypertension, 533
 - in multiple gestation, 564
- Fetal demise, of sibling(s), with multiple gestation, 57
- Fetal growth
 - deficiency, in oligohydramnios tetrad, 817
 - retardation, in twins versus singletons, 31
- Fetal heart rate
 - and intrauterine infection with PPROM, 849
 - monitoring, historical perspective on, 647
 - with preterm premature rupture of membranes, 849, 870
 - tachysystole, cervical ripening and, 606
- Fetal lung maturation
 - acceleration of, methods for, 564
 - evaluation of, 503
 - in multiple gestation, 564
 - preterm premature rupture of membranes and, 503, 832, 870
 - in twins, 564
- ultrasound evaluation of, with premature rupture of membranes, 817, 870
- Fetal macrosomia. *See* Macrosomia
- Fetal movement counting, 647
- Fetal movement profile, 647
- Fetal presentation, noncephalic, with preterm premature rupture of membranes, 503
- Fetal scalp blood sampling, for determination of fetal platelet count, 436
- Fetal surveillance. *See also* Antepartum testing: Fetal assessment
 - methods of, 647
- Fetal well-being
 - evaluation
 - in management of preterm premature rupture of membranes, 870
- Fetal well-being, evaluation, 67
- Fever
 - maternal, intrapartum, epidural analgesia and, 449
 - postpartum, with trial of labor after cesarean delivery, 369
 - puerperal, with trial of labor after cesarean delivery, 369
- Fibronectin, fetal, and preterm labor/delivery, 95, 481, 491
- Fistula
 - bladder, 764
 - ureterovaginal, postoperative, repair of, 755
 - urinary, postoperative, 719, 755
 - location of, identification of, 755
 - repair of, 755
 - spontaneous healing of, 755
 - vesicovaginal, postoperative, repair of, 755
- Flavoxate hydrochloride, for urinary incontinence, 691
- Fluoxetine, for premenstrual syndrome, effectiveness of, 405
- Foley catheter
 - advantages and disadvantages of, 735
 - placement technique for, 735
 - in postoperative bladder drainage, 735
- Follicles, primordial, age-related decrease in, 895, 913, 951, 958
- Follicle-stimulating hormone
 - levels, in older infertile woman, 940
 - secretion
 - age-related alterations in, 898, 921
 - age-related changes in, 913
 - serum level, diagnostic of menopause, 958
- Follicular atresia, 895, 898, 913, 951, 958
- Forced expiratory volume in 1 second, measurement of, with asthma in pregnancy, 555
- Fragmin. *See* Dalteparin
- Fundamental Biostatistics, 4th edition (Rosner), 257
- Gallbladder disease, hormone replacement therapy and, 966
- Gastroschisis
 - clinical characteristics of, 393
 - embryology of, 393
 - incidence of, 393
 - prenatally diagnosed, prophylactic cesarean delivery for, 393
- Gender, and neonatal mortality with multiple gestation, 57

- Gene therapy, for p53 tumor suppressor gene mutations, 172
- Genetic counseling
about cancer risk, 141
in absence of single gene disorder, 141
for Mendelian disorders, 141
relevant to multiple gestation, 564
- Genetic testing, for cancer risk assessment, 141
in absence of family history of cancer, 141
BRCA1 and BRCA2 gene mutations and, 141, 157
confidentiality of, 141, 157
results, informing individuals of, 141
- Genitourinary atrophy, perimenopausal, 921, 966, 976
- Gentamicin, for pyelonephritis, 515
- Genuine stress incontinence. See Urinary incontinence, stress/genuine stress
- Geographic area, multiple birth rates and, 3
- Gestation, optimal length of, for twins, 31
- Gestational age
and delivery of multifetal pregnancy, 31
and perinatal morbidity and mortality, with twin versus singleton births, 3, 13, 31
population-based data on, 3
of twins, relationship to intrauterine growth and birth weight, 57, 115
- Gestational age-dependent morbidity, preterm premature rupture of membranes and, 461, 827, 832
- Gestational diabetes
definition of, 584
diagnosis of, 584
epidemiology of, 584
exercise and, 584
fetal risks with, 332
screening for, 564, 584
U.S. Preventive Services Task Force recommendations on, 332
treatment of, 332
- Gestational trophoblastic disease, hyperemesis gravidarum with, 597
- Gilda Radner Familial Ovarian Cancer Registry, 215
- Ginger, powdered, for hyperemesis gravidarum, 597
- Glucocorticoids
adverse effects and side effects of
fetal effects of, 436
maternal, in pregnancy, 436
for idiopathic thrombocytopenic purpura in pregnancy, 436
- Glucose tolerance, hormone replacement therapy and, 966
- Glycopyrrolate, for urinary incontinence, 691
- Gonadotropin-releasing hormone agonists
ovulation suppression by, for premenstrual syndrome, effectiveness of, 405
for women with dysfunctional uterine bleeding, 928
- Gonadotropins, age-related changes in, 913
- Goserelin, ovulation suppression by, for premenstrual syndrome, effectiveness of, 405
- Gram stain, amniotic fluid, in diagnosis of intrauterine infection with PPROM, 849
- Granulosa cells, age-related alterations in, 898
- GSI. See Urinary incontinence, stress/genuine stress
- Gynecologic cancer. See also Breast cancer; Cervical cancer; Ovarian cancer
familial
chemoprevention, 200
early detection, 200
epidemiology, 200
risk reduction, 200
human papillomavirus and, 172
p53 tumor suppressor gene and, 172
- Halban syndrome, 928
- Healthcare costs, in United States, 296
- Healthcare evaluation
indicator in, 348
outcome in, 348
process for, 348
structure for, 348
- Health Plan Employer Data and Information Sets, 481
- HELLP syndrome, with hypertension in pregnancy, 533
- Helsinki Ultrasound Trial, 67
- Hematuria, with cystitis, 744
- Hemoglobin, glycosylated, in pregnant diabetic, 584
- Hemorrhage. See also Bleeding
intrauterine, preterm premature rupture of membranes and, 461, 827, 832, 864, 870
postpartum, with multiple gestation, 79, 85
- Heparin
adverse effects and side effects of, 545
low-molecular-weight
advantages of, 545
dosage and administration of, 545
indications for, 545
mechanism of action of, 545
physicochemical properties of, 545
safety in pregnancy, 545
mechanism of action of, 545
neutralization, with protamine sulfate, 545
pharmacokinetics of, 545
resistance, 545
therapy
bleeding caused by, 545
complications of, 545
dosage and administration of, 545
indications for, 545
osteoporosis with, 545
in pregnancy, 545
for prophylaxis, 545
thrombocytopenia induced by, 545
- Hereditary flat adenoma syndrome, 172
- Hereditary nonpolyposis colorectal cancer (HNPCC), 167, 172, 200
population screening for, 200
prophylactic surgery and, 215
- Historical controls (HCTs)
bias occurring with use of, 245
retrospective studies using, 449
- Home care
antepartum, for high-risk pregnancy
advantages and disadvantages of, 626
versus hospitalization, 626
prescription of, practices in, 481
psychosocial effects of, 626
stressors related to, 626
for hypertension in pregnancy, 533
- Home management, of preterm premature rupture of membranes, 481, 503, 870
- Home monitoring devices, in predicting preterm labor/delivery, 95

- Home uterine activity monitoring
 - for detection of risk of preterm delivery, 491
 - U.S. Preventive Services Task Force recommendations on, 332
- Hormone replacement therapy. *See also* Estrogen replacement therapy
 - contraindications to, 966
 - perimenopausal, 951
 - compliance with, 966
 - regimens for, 966
 - postmenopausal, 951
 - risk/benefit assessment for, 966
 - screening for risk and initiating prevention for, 966
- Hospitalization
 - for abruptio placentae, 527
 - alternatives to, 481
 - antepartum, for high-risk pregnancy
 - advantages and disadvantages of, 626
 - boredom with, reduction of, 626
 - family integrity and, 626
 - versus home care, 626
 - length of, stressors related to, 626
 - patient's participation in care and, 626
 - patient's sense of control and, 626
 - prescription of, practices in, 481
 - psychosocial effects of, 626
 - psychosocial interventions in, evaluation of effectiveness of, 626
 - stressors related to, 626
 - for childbirth, historical perspective on, 611
 - for hypertension in pregnancy, 533
 - for idiopathic thrombocytopenic purpura in pregnancy, 436
 - in management of preterm premature rupture of membranes, 503, 870
 - for placenta previa, 481, 527
 - postpartum
 - early discharge from. *See* Early postpartum discharge
 - purposes of, 611
 - recommended length of stay, 611
 - for pyelonephritis, rationale for, 515
- Hot flashes, in perimenopause, 921, 966, 976
- HUAM. *See* Home uterine activity monitoring
- Human chorionic gonadotropin, and hyperemesis gravidarum, 597
- Human papillomavirus (HPV), and gynecologic cancer, 172
- Hydramnios
 - with diabetes in pregnancy, 584
 - in twin gestation, 37, 85, 105
- Hydration, intravenous, in preterm labor, 491
- Hydrops fetalis, hyperemesis gravidarum with, 597
- Hyoscyamine, for urinary incontinence, 691
- Hyoscyamine sulfate, for urinary incontinence, 691
- Hyperbilirubinemia, neonatal, and early postpartum discharge, 611
- Hyperemesis gravidarum
 - acupressure for, 597
 - ambulatory care for, 481
 - antiemetics for, 597
 - associated obstetric conditions, 597
 - bendectin for, 597
 - corticosteroids for, 597
 - definition of, 597
 - depression with, 597
 - differential diagnosis of, 597
 - doxylamine for, 597
 - enteral or parenteral nutrition in, 597
 - etiology of, 597
 - fetal complications of, 597
 - gastrointestinal considerations with, 597
 - hormonal considerations with, 597
 - human chorionic gonadotropin and, 597
 - incidence of, 597
 - intravenous hydration for, 597
 - laboratory abnormalities in, 597
 - management of, 597
 - maternal complications of, 597
 - methylprednisolone for, 597
 - ondansetron for, 597
 - powdered ginger for, 597
 - prochlorperazine for, 597
 - promethazine for, 597
 - psychologic considerations with, 597
 - pyridoxine for, 597
 - related symptoms, 597
 - skilled nursing facility criteria for, 481
 - somatization with, 597
 - thiamine replacement with, 597
 - treatment algorithm for, 597
 - trimethobenzamide for, 597
- Hypertension
 - chronic
 - clinical features of, 533
 - definition of, 533
 - definition of, 533
 - with diabetes in pregnancy, 584
 - gestational. *See also* Antihypertensive therapy; Preeclampsia; Pregnancy-induced hypertension
 - clinical features of, 533
 - outpatient management of, studies of, 533
 - hormone replacement therapy and, 966
 - with multiple gestation, 79
 - in pregnancy. *See also* Antihypertensive therapy; Hypertension, chronic; Hypertension, gestational; Preeclampsia; Pregnancy-induced hypertension
 - in adolescents, management of, 533
 - ambulatory management of, 533
 - fetal assessment with, 533
 - hospitalization for, 533
 - mild, indications for delivery with, 533
 - nonproteinuric, management of, 533
 - outpatient management of, studies of, 533
 - proteinuric, management of, 533
 - symptoms requiring immediate evaluation in, 533
 - pregnancy-induced. *See* Pregnancy-induced hypertension
 - transient, definition of, 533
 - and urinary incontinence, 663
- Hyperthyroidism, abnormal uterine bleeding with, 928
- Hypertriglyceridemia, estrogen replacement therapy and, 966
- Hypothesis test
 - definition of, 257
 - operating characteristics of, 257
- Hypothyroidism
 - abnormal uterine bleeding with, 928

- age-related incidence of, 928
- screening for, after early postpartum discharge, 611
- Hysterectomy
 - for chronic pelvic pain, 422
 - intraoperative identification of enterocele in, 786
 - and ovarian cancer risk reduction, 200
 - pelvic floor reconstruction and/or management during, 786
 - rate, social influence model of intervention and, 348
 - risk of, with trial of labor after cesarean delivery, 369
 - in treatment of dysfunctional uterine bleeding, 928
- Hysteroscopy, in patient with abnormal uterine bleeding, 928
- Hytrin. See Terazosin chloride
- Ibuprofen (Motrin)
 - for chronic pelvic pain, 422
 - for women with dysfunctional uterine bleeding, 928
- Idiopathic thrombocytopenic purpura (ITP)
 - bleeding with, 436
 - clinical characteristics of, 436
 - diagnosis of, 436
 - unnecessary/inappropriate tests in, 436
 - epidemiology of, 436
 - management of, in pregnancy, 436
 - in pregnancy
 - fetal adverse effects of, 436
 - management of, 436
 - fetal considerations, 436
 - maternal considerations, 436
 - practice guidelines for, 436
 - maternal adverse effects of, 436
 - sex distribution of, 436
 - signs and symptoms of, 436
- Imipramine (Tofranil)
 - for chronic pelvic pain, 422
 - for urinary incontinence, 691, 702
- Incremental cost-effectiveness, 296
- Indwelling transurethral catheter
 - advantages and disadvantages of, 735
 - placement technique for, 735
 - in postoperative bladder drainage, 735
- Infants of diabetic mothers
 - congenital malformations in, 584
 - neonatal morbidity in, 584
- Infection(s). See also Urinary tract infections
 - intra-amniotic, with preterm premature rupture of membranes, tests for, 503
 - intrauterine, with preterm premature rupture of membranes, 503, 827, 849, 870
 - amniotic fluid tests for, 849
 - blood tests for, 849
 - diagnosis of, 849
 - fetal biophysical testing for, 849
 - maternal urinary cytokines and, 849
 - microbiology of, 864, 870
 - monitoring of patients with, recommendations for, 849
 - neonatal, with preterm premature rupture of membranes, 503, 827, 849
 - postpartum, preterm premature rupture of membranes and, 461
 - and premature rupture of membranes, 810
 - antenatal corticosteroids and, 832
 - umbilical artery systolic-to-diastolic blood flow (S/D) ratio and, 849
 - urinary catheter-related, 735
- Infertility treatment
 - conventional, success, maternal age-related incidence of, 958
 - decision making about, infertile couple's participation in, 127
 - and multifetal gestation, 3, 47, 57, 79, 127
 - options for, 127
- Inflammatory bowel disease, chronic pelvic pain with, 422
- Inhibin secretion, age-related alterations in, 898, 913, 921
- Institute of Medicine (IOM), perspective on practice guidelines, 343
- Instrument use, in delivery, effects of epidural analgesia on, 449
- Insulin-like growth factor-I, and age-related ovarian changes, 898
- Insulin therapy, in pregnancy, 584
- Interleukin-6
 - amniotic fluid, and intrauterine infection with PPROM, 849
 - maternal serum, in diagnosis of intrauterine infection with PPROM, 849
- Interleukin-1 β , amniotic fluid, and intrauterine infection with PPROM, 849
- Interstitial cystitis, 764
- Interviewing techniques, for telephone contacts, 640
- Intracranial hemorrhage (ICH)
 - prevention, in obstetric treatment of women with ITP, 436
 - in thrombocytopenic fetuses, prevention, 436
- Intrauterine device (IUD), 951
 - and pelvic inflammatory disease, case-control study of, evaluation of, 235
 - for women with ovulatory dysfunctional uterine bleeding, 928
- Intrauterine growth
 - evaluation, 67
 - of twins
 - discordant, 57, 67, 105
 - relationship to birth weight and gestational age, 57, 115
- Intrauterine growth restriction
 - with hypertension in pregnancy, 533
 - in multiple gestation, 564
 - in twin pregnancy, 564
- Intravenous immune globulin (IVIg)
 - adverse effects and side effects of, 436
 - for idiopathic thrombocytopenic purpura in pregnancy, 436
- Intravenous pyelography, in pregnancy, 515
- Intraventricular hemorrhage, preterm premature rupture of membranes and, 461, 827, 864, 870
 - antenatal corticosteroids and, 832
- In vitro fertilization
 - gonadotropin-stimulated, alternatives to, 127
 - multifetal gestation and, 127
 - pregnancy complications with, 79
 - success, maternal age-related incidence of, 958
 - success rates, in older women, 940
- Irritable bowel syndrome
 - chronic pelvic pain and, 422

- diagnostic criteria for, 422
- medical therapy for, 422
- Joint Commission on Accreditation of Healthcare Organizations (JCAHO), quality of care measures, 348
- Kegel exercises
 - clinical applications of, 702
 - efficacy of, 702
 - techniques for, 702
- Klebsiella, urinary tract infection caused by, 744
- Labetalol
 - adverse effects and side effects of, 533
 - antihypertensive effect, mechanism of action of, 533
 - in pregnancy
 - dosage and administration of, 533
 - studies of, 533
- Labor. *See also* Trial of labor
 - induction of
 - in management of premature rupture of membranes in term patients, 883
 - in management of preterm premature rupture of membranes, 503
 - and trial of labor after cesarean delivery, 369
 - preterm
 - activity restrictions with, 491
 - ambulatory management of, 491
 - bed rest for, 491
 - cervical length and, 491
 - with diabetes in pregnancy, 584
 - diagnosis of, 491
 - epidemiology of, 491
 - gestational age at prior preterm birth and, 491
 - inpatient treatment of, 491
 - management of, 481, 491
 - in multifetal gestation, 95
 - home monitoring devices for predicting, 95
 - in multiple gestation, 564
 - with preterm premature rupture of membranes, 503
 - prevention of, 13, 491
 - pyelonephritis and, 515
 - recurrence risk, 491
 - risk factors for, 491
 - signs and symptoms of, 491
 - skilled nursing facility criteria for, 481
- Lambda sign, with dichorionic placentas, 67
- Laparoscopy
 - for detection of ovarian cancer, 200
 - in evaluation of chronic pelvic pain, 422
 - operative, for chronic pelvic pain, 422
 - in repair of urinary tract injury, 755
 - lighted stents for, 755
- Laser surgery, in treatment of dysfunctional uterine bleeding, 928
- Lecithin/sphingomyelin ratio, 832
- Leukocyte count, maternal, in diagnosis of intra-amniotic infection, 503
- Leukocyte esterase, amniotic fluid, and intrauterine infection with PPROM, 849
- Leukocyte esterase test, for urinary tract infections, 744
- Leuprolide acetate, ovulation suppression by, for premenstrual syndrome, effectiveness of, 405
- Levator syndrome, 422
 - treatment of, 422
- Levsin. *See* Hyoscyamine
- Levsin SL. *See* Hyoscyamine sulfate
- Lidocaine (Xylocaine), for trigger point treatment, 422
- Life style modifications, in twin gestation, 85
 - and prevention of preterm delivery, 13
- Li-Fraumeni syndrome, 172
 - genetics of, 172
- Likelihood ratio (LR), 267
 - updating diagnostic probabilities using, 267
- Linkage analysis, for cancer risk assessment, 141
- Lioresal. *See* Baclofen
- Literature
 - assessment of, 307
 - guides to, 307
 - interpretation of, 307
- Literature reviews, 275
 - in meta-analysis, 275
- Local anesthetics
 - for epidural analgesia. *See also* Epidural analgesia
 - concentration of, effects on malposition, instrument use, vaginal delivery, and cesarean delivery, 449
 - for trigger point treatment, 422
 - Lorazepam, for voiding dysfunctions, 691
- Lovenox. *See* Enoxaparin
- Low birth weight, rate, in twins versus singletons, 13, 31
- Low-birth-weight infants, in multiple gestations, 564
- Luteinizing hormone, secretion, age-related changes in, 913
- Lynch syndrome II, 167, 172, 200
- Macrosomia
 - with diabetes in pregnancy, 584
 - glycemic control and, 584
 - with gestational diabetes, 332
 - and trial of labor after cesarean delivery, 369
- Malposition, effects of epidural analgesia on, 449
- Managed care
 - and ambulatory obstetric management, 481
 - and quality of care, 481
- Markov models, 282
- Marshall-Bonney test, for urinary incontinence, 663
- Marshall-Marchetti-Krantz procedure, 712, 786
- Mastectomy, prophylactic, and breast cancer risk reduction, 215
- Maternal age
 - and aneuploidy, 958
 - and chromosomal abnormalities, 898, 940, 958
 - and multifetal gestation, 3, 57, 79
 - and success of infertility treatment, 958
 - and triplet gestation, 3
 - and twin gestation, 3
- Maternal mortality
 - causes, 79
 - multifetal pregnancy and, 79
 - French data on, 79
 - in spontaneous versus iatrogenic pregnancy, 79
 - rates, in singleton and multiple pregnancies, 79
 - risk factors for, 79
 - with trial of labor after cesarean delivery, 369
- Medical review criteria, definition of, 343
- Medroxyprogesterone (Provera), for ovarian cycle suppression, with chronic pelvic pain, 422
- Mefenamic acid (Ponstel)

- for chronic pelvic pain, 422
- for premenstrual syndrome, possible effectiveness of, 405
- for women with dysfunctional uterine bleeding, 928
- Meiosis, errors in, maternal age-related incidence of, 898, 958
- Melanoma, 172
- Membrane stripping, 606
- Meningomyelocele, prophylactic cesarean delivery for, 393
- Menopause. See also Perimenopause
 - age at, 951
 - definition of, 895
 - evaluation for, 951
- Menopause transition, age at, 976
- Menstrual cycle length, in perimenopause, 913, 921, 928, 976
- Menstrual pattern, in perimenopause, 913, 921, 928, 951, 976
- Menstruation, normal, 928
- Mental status, assessment of, in patient with urinary incontinence, 663
- Meta-analysis. See also Cochrane Collaboration
 - acceptance of, 275
 - application of, in obstetrics and gynecology, 275
 - benefits of, 275
 - criticisms of, 275
 - cumulative, 275, 362
 - definition of, 275
 - of efficacy of electronic fetal monitoring, 275, 362
 - heterogeneity testing in, 362
 - literature search used in, 362
 - morbidity outcomes in, 362
 - perinatal death outcomes in, 362
 - quality of clinical trials and, criteria used to assess, 362
 - results, 362
 - safety outcomes in, 362
 - statistical methods used in, 362
 - summary outcomes in, 362
 - evaluation of, 307
 - literature reviews in, 275
 - published, assessment of, 275
 - steps in, 275
 - usefulness of, factors affecting, 275
- Methotrexate (MTX)
 - local, in management of ectopic pregnancy, 382
 - systemic, in management of ectopic pregnancy, 382
- Methylodopa
 - antihypertensive effect, mechanism of action of, 533
 - in pregnancy
 - dosage and administration of, 533
 - safety of, 533
 - studies of, 533
- Methylprednisolone, for hyperemesis gravidarum, 597
- Metoclopramide, for urinary incontinence, 691
- Mezlocillin
 - for preterm premature rupture of membranes, 864
 - for pyelonephritis, 515
- Mifepristone, for cervical ripening, 606
- Migraine, in perimenopause, 921, 976
- Mineral supplements, for premenstrual syndrome, possible effectiveness of, 405
- Mittelschmerz, and chronic pelvic pain, 422
- Molecular genetic testing
 - advantages and disadvantages of, 141
 - for cancer risk assessment, 141
- Mothers of Super Twins (MOST), 127
- MSAFP. See Alpha-fetoprotein, maternal serum levels
- Multifetal pregnancy
 - iatrogenic
 - prevention, 47, 127
 - risk, 47, 57
 - and maternal mortality
 - French data on, 79
 - with iatrogenic versus spontaneous pregnancy, 79
- Multifetal pregnancy reduction (MFPR), 127, 564
 - ethical considerations, 47
 - fetal number
 - finishing, and outcome, 47
 - starting, and outcome, 47
 - obstetric outcome with, 47
 - postprocedure concerns, 47
 - pregnancy loss with, 47
 - preterm delivery with, 47
 - and selective termination, comparison of, 47
 - technical considerations, 47
- Multiple gestation. See also Multifetal pregnancy
 - ambulatory management of, 564
 - anemia in, 564
 - assisted reproductive technology and, 564
 - attitudes toward, in infertile couples, 127
 - biophysical profile in, 564
 - cervical cerclage in, 564
 - cesarean delivery for, and maternal mortality, 79
 - congenital anomalies in, 564
 - contraction stress testing in, 564
 - demographic variables related to, 3, 79
 - desire for, in infertile couples, 127
 - epidemiology of, 564
 - fetal assessment in, 564
 - fetal complications, in antepartum period, 564
 - fetal demise of sibling(s) with, 57
 - fetal/intrauterine growth in
 - maternal factors affecting, 57, 115
 - patterns, in United States, 115
 - and singleton fetal growth, comparison, 115
 - fetal lung maturity evaluation in, 564
 - fetal mortality with, 564
 - frequency, trends in, 79
 - genetic counseling relevant to, 564
 - higher order
 - delivery route for, 25
 - resources for couple with, 127
 - hyperemesis gravidarum with, 597
 - hypertension with, 79
 - incidence, trends in, 57, 115
 - incidence of, 564
 - intrapartum management of, 25, 31
 - intrauterine growth restriction in, 564
 - laboratory evaluations in, 564
 - low-birth-weight infants in, 564
 - maternal adaptation to, 57
 - maternal complications of, 564
 - maternal disorders associated with, 79
 - maternal morbidity and mortality with, 79
 - maternal serum alpha-fetoprotein levels in, 564
 - maternal weight gain with, 57
 - neonatal mortality with, 57, 115, 564
 - NICU admission rates with, 564

- nonstress test in, 564
- perinatal mortality with, 57, 115, 564
- postpartum hemorrhage with, 79, 85
- preeclampsia in, 564
- pregnancy loss in, 37, 127
- risk factors for, 57
- single fetal demise in, management of, 564
- sonographic examination in, 564
- and trial of labor after cesarean delivery, 369
- Multiple sclerosis, chronic pelvic pain with, 422
- Musculoskeletal factors, in chronic pelvic pain, 422
- medical management of, 422
- Mutation analysis, direct, for cancer risk assessment, 141
- Myocardial infarction
 - oral contraceptives and, 951
 - risk factors for, 951
- Myofascial pain, abdominal, 422
- Naproxen (Naprosyn), for chronic pelvic pain, 422
- Naproxen sodium (Anaprox)
 - for chronic pelvic pain, 422
 - for premenstrual syndrome, possible effectiveness of, 405
 - for women with dysfunctional uterine bleeding, 928
- National Committee on Quality Assessment, 481
- National Organization of Mothers of Twins Clubs, Inc. (NOMOTC), 85
- Nausea and vomiting, in pregnancy. *See also* Hyperemesis gravidarum
 - antiemetics for, 597
 - disability from, 597
 - diurnal variation in, 597
 - duration of, 597
 - onset of, 597
 - prevalence of, 597
 - severity of, 597
 - spectrum of, 597
- Necrotizing enterocolitis, antibiotic therapy for preterm premature rupture of membranes and, 461, 827, 864
- Negative predictive value, of diagnostic tests, calculation of, 267
- Neonatal infection, preterm premature rupture of membranes and, 461, 503, 827, 849
- Neonatal intensive care, economic evaluation of, 296
- Neonatal intensive care unit
 - admissions, with multiple gestation, 564
 - familiarization of parents with, in high-risk pregnancy, 626
 - length of stay in, with multiple gestation, 564
- Neonatal mortality, with multiple gestation, factors affecting, 57
- Neonatal purpura fulminans, 545
- Neural tube defects
 - clinical characteristics of, 393
 - genetics of, 393
 - incidence of, 393
 - prenatally diagnosed, prophylactic cesarean delivery for, 393
 - risk factors for, 393
- Neurofibromatosis, 172
 - chronic pelvic pain with, 422
- Neurologic examination, urologically oriented, in patient with urinary incontinence, 663
- Newborn
 - after early postpartum discharge
 - follow-up examination of, 611
 - genetic screening tests for, 611
 - hyperbilirubinemia in, 611
 - problems of, 611
 - rehospitalization rates for, 611
 - deaths, with preterm premature rupture of membranes, 503, 827
 - infections of, with preterm premature rupture of membranes, 461, 503, 827, 849
 - with preterm premature rupture of membranes, complications in, 503, 827
 - pulmonary hypoplasia, with preterm premature rupture of membranes, 503, 827
- Newborn care, systematic reviews of, 315
- Newborns' and Mothers' Health Protection Act of 1996, 611
- NICHD-MFMU multicenter trial, of antibiotic therapy for preterm premature rupture of membranes, 461
- NICU. *See* Neonatal intensive care unit
- Nifedipine
 - adverse effects and side effects of, 533
 - antihypertensive effect, mechanism of action of, 533
 - in pregnancy
 - dosage and administration of, 533
 - safety of, 533
 - studies of, 533
 - for urinary incontinence, 691
- Nitrazine test, for amniotic fluid, with rupture of membranes, 503
- Nitrite dipstick test, for urinary tract infections, 744
- Nitrofurantoin suppression, for pyelonephritis, 515
- Nonsteroidal anti-inflammatory drugs
 - for premenstrual syndrome, possible effectiveness of, 405
 - for women with dysfunctional uterine bleeding, 928
- Nonstress test
 - advantages of, 647
 - clinical applications, 647
 - and intrauterine infection with PPROM, 849, 870
 - in multiple gestation, 564
 - reactive, 647
 - ultrasound artifact and, 647
- Norephedrine, for urinary incontinence, 691
- Norfenefrine, for urinary incontinence, 691
- nQuery Advisor, 257
- Null hypothesis, 257
- Nutrition, and cancer risk reduction, 200
- Obesity, and urinary incontinence, 663
- Observational studies, 235. *See also* Case-control studies; Cohort studies
 - bias in, 235
 - sample size calculation for, 257
 - types of, 235
- Obstetric care. *See also* Ambulatory obstetric management
 - costs of, 481
 - reduction, methods for, 481
- Odds ratio, calculation of, 235
- Oligohydramnios
 - with preterm premature rupture of membranes, 503
 - and intrauterine infection, 849

- in twin gestation, 37, 85, 105
- Oligohydramnios tetrad, 817
 - fetal anomalies in, 817
 - fetal growth deficiency in, 817
 - Potter's facies in, 817
 - prediction of, 817
 - pulmonary hypoplasia in, 817
 - risk factors for, 817
- Omphalocele
 - clinical characteristics of, 393
 - embryology of, 393
 - incidence of, 393
 - prenatally diagnosed, prophylactic cesarean delivery for, 393
- Ondansetron, for hyperemesis gravidarum, 597
- One-way sensitivity analysis, 282
- Oocyte(s)
 - age-related changes in, 898, 940
 - development of, 898
 - number of, 898
- Oocyte aspiration, 127
- Oocyte donation, pregnancy rates with
 - maternal age-related incidence of, 958
 - in older women, 940
 - ethical considerations with, 940
 - obstetrical outcome with, 940
- Oophorectomy
 - for premenstrual syndrome, effectiveness of, 405
 - prophylactic, and ovarian cancer risk reduction, 200, 215
- Operative injury, with trial of labor after cesarean delivery, 369
- Optivite, for premenstrual syndrome, possible effectiveness of, 405
- Oral contraceptives
 - and cancer risk reduction, 200
 - combination, for premenstrual syndrome, ineffectiveness of, 405
 - noncontraceptive benefits of, 951
 - for ovarian cycle suppression, with chronic pelvic pain, 422
 - in perimenopause, 958, 976
 - use rates, by age, 951
 - for women with dysfunctional uterine bleeding, 928
- Osteoporosis
 - with heparin therapy, 545
 - in perimenopause, 966, 976
- Outpatient care, in obstetrics/gynecology, applications of, 640
- Ovarian cancer
 - epidemiology, 200, 215
 - familial, 157, 172, 200
 - chemoprevention, 200
 - epidemiology, 200, 215
 - histologic changes and, 215
 - prophylactic surgery and, 215
 - risk assessment, genetic testing for, 141
 - risk reduction, 200
 - lifetime risk of, 215
 - mortality, 215
 - population screening for, 200, 215
 - p53 tumor suppressor gene and, 172
 - risk factors for, 200
 - screening
 - evaluation of, study design for, 267
 - tests for, 200, 215
 - U.S. Preventive Services Task Force recommendations on, 332
 - survival, 215
- Ovarian cycle suppression (ovulation suppression)
 - for chronic pelvic pain, 422
 - for premenstrual syndrome, effectiveness of, 405
- Ovarian hyperstimulation, controlled, 127
- Ovarian hyperstimulation syndrome (OHSS), 127
- Ovarian reserve, age-related alterations in, 898, 921
- Ovary(ies)
 - age-related endocrine alterations in, 895, 898, 913
 - aging of, 913
 - anatomy of, 898, 913
 - functional activity of, age-related changes in, 895, 898, 913
 - perimenopausal changes in, 895, 898, 913, 921
- Ovulation
 - in perimenopause, 921, 951, 976
 - physiology of, 898
- Ovulation induction
 - controlled drift with, 127
 - gonadotropin-stimulated
 - alternatives to, 127
 - contraindications to, 127
 - hyperstimulation and, 127
 - multiple gestation rate with, 564
 - in older women
 - cancer risk and, 940
 - success rates, 940
 - prolonged low-dose stimulation for, 127
 - standard regimens for, 127
- Oxford Database of Perinatal Trials (ODPT), 315
- Oxybutynin chloride, for urinary incontinence, 691
- Pain
 - acute
 - characteristics of, 422
 - versus chronic pain, 422
 - definition of, 422
 - chronic. See also Chronic pelvic pain
 - versus acute pain, 422
 - biopsychosocial models of, 422
 - characteristics of, 422
 - definition of, 422
 - perception, theories of, 422
- Pap smear, incremental cost-effectiveness of, 296
- Para-aminomethylbenzoic acid, for women with dysfunctional uterine bleeding, 928
- Parenteral nutrition, in hyperemesis gravidarum, 597
- Parents, of multiples
 - preparation of, 85
 - self-help groups for, 85
- Paroxetine, for premenstrual syndrome, effectiveness of, 405
- Peak expiratory flow rate, monitoring, with asthma in pregnancy, 555
- Pearson's chi-square statistic, 257
- Pelvic adhesions, chronic pelvic pain with, 422
- Pelvic examination, in patient with urinary incontinence, 663
- Pelvic floor defects/disorders. See also Pelvic organ prolapse
 - apical, identification of, 663
 - central, identification of, 663

- central and paravaginal, coexisting, identification of, 663
- chief problem in, 657
- diagnosis of, initial assumptions for, 657
- history-taking with, 657
- identification of, 663
- paravaginal, identification of, 663
- patient with
 - current symptoms of, 657
 - interspecialty communication about, 657
 - primary care for, 657
 - requests for old records of, 657
 - review of medications with, 657
 - review of old records of, 657
 - urinary diary for, 657
 - written history from, 657
 - written review of systems for, 657
- surgical management of. *See also* Urinary incontinence, surgical management of
 - review of old records of, 657
 - success of, factors affecting, 657
 - symptom assessment with, USA method for, 657
- transverse, identification of, 663
- treatment of, goals for, 657
- Pelvic floor muscle
 - physiology of, 702
 - strengthening
 - biofeedback for, 702
 - electrical stimulation for, 702
 - Kegel exercises for, 702
 - in management of urinary incontinence, 702
 - vaginal cones for, 702
- Pelvic inflammatory disease (PID)
 - and intrauterine device, case-control study of, evaluation of, 235
 - ultrasound diagnosis of, evaluation of, study design for, 267
- Pelvic organ prolapse. *See also* Pelvic floor defects/disorders
 - anterior compartment support defects causing, 777
 - surgical approach to, 786
 - anterior vaginal. *See also* Cystocele; Cystourethrocele; Urethrocele
 - etiology of, 786
 - pathogenesis of, 786
 - types of, 786
 - apical vaginal
 - surgical management of, 786
 - types of, 786
 - clinical classification of, 786
 - indications for referral to urogynecology subspecialist, 672
 - posterior vaginal. *See also* Enterocoele; Rectocoele
 - surgical management of, 786
 - types of, 786
 - reduction maneuvers, for urodynamic evaluation, 672
 - surgical management of, 786
 - abdominal approach for, 777, 786
 - development of stress incontinence after, 777
 - goals of, 777
 - intracardinal pubovesicocervical imbrication for, 777
 - needle suspensions for, 712
 - operative technique, 777
 - outcome, factors affecting, 786
 - paraurethral fascial sling urethropexy for, 777
 - patient information about, 777, 786
 - patient selection for, 786
 - periurethral injections for, 712
 - postoperative rules with, 777
 - preoperative evaluation for, 777
 - principles and rationale for, 786
 - procedure for, 777
 - sling procedures for, 712, 777, 786
 - vaginal approach for, 777, 786
 - vaginal paravaginal defect repair for, 777
 - urinary incontinence with, 777
 - urinary symptoms with, 777
 - urodynamic evaluation of patient with, 672
 - Pelvic pain, chronic. *See* Chronic pelvic pain
 - Pelvic reconstructive surgery. *See* Pelvic organ prolapse, surgical management of
 - Pelvic support, anatomy and pathophysiology of, 719
 - Penicillin, for preterm premature rupture of membranes, 461, 864, 870
 - Percutaneous umbilical cord ligation, 564
 - Performance measures, definition of, 343
 - Perimenopause, 894, 895
 - abnormal uterine bleeding in, 921, 976
 - bleeding problems in, 928
 - cardiovascular disease in, 966, 976
 - definition of, 895, 921, 976
 - depression in, 921, 976
 - duration of, 895, 921
 - estrogen replacement in, 976
 - fertility in, 921, 958, 976
 - fertility treatment in, success, age-related incidence of, 958
 - follicular volume changes in, 921
 - genitourinary atrophy in, 921, 966, 976
 - hormonal patterns in, 913, 921, 966, 976
 - hot flashes in, 921, 966, 976
 - menstrual pattern in, 913, 921, 951, 976
 - migraine in, 921, 976
 - obstetrical outcome in, 958
 - oral contraceptive use in, 951, 958, 976
 - osteoporosis in, 966, 976
 - ovarian changes in, 898, 921, 951
 - ovulation in, 951, 976
 - pregnancy in, 921, 951, 958, 976
 - psychological/cognitive disturbances in, 921, 966, 976
 - risk assessment in, 966
 - sexual function in, 921, 976
 - sleep disturbances in, 921, 976
 - somatic symptoms in, 921, 976
 - symptoms of, 921
 - timing of, 895, 921
 - vasomotor instability in, 921, 951, 966, 976
 - vulvovaginal effects in, 921, 966, 976
 - Perinatal morbidity and mortality
 - by gestational age, for twins versus singletons, 3, 13, 31
 - in multifetal pregnancy, 57
 - preterm premature rupture of membranes and, 461, 827, 870
 - with trial of labor after cesarean delivery, 369
 - Perinatal mortality rate
 - for singletons, by gestational age, 3, 13, 31
 - for twins, by gestational age, 3, 13, 31

- Perineal sensation, assessment of, in patient with urinary incontinence, 663
- Perinometer, 702
- Periventricular leukomalacia, preterm premature rupture of membranes and, 832
- Pessaries, in management of urinary incontinence, 702
- Phenoxybenzamine
adverse effects and side effects of, 691
for voiding dysfunctions, 691
- Phenylketonuria, screening for, after early postpartum discharge, 611
- Phenylpropanolamine, for urinary incontinence, 691, 702
- PIH. See Pregnancy-induced hypertension
- Piperacillin
for preterm premature rupture of membranes, 864
for pyelonephritis, 515
- Placenta, monochorionic, 105
- Placental abruption. See Abruptio placentae
- Placenta previa
clinical presentation of, 527
definition of, 527
delivery and, 481
detection of, 527
expectant management of, 527
hemorrhage with, 481
home care for, 481
hospitalization for, 481, 527
incidence of, 527
outpatient care for, 527
partial, 527
risk factors for, 527
skilled nursing facility criteria for, 481
uterine contractions with, 527
vaginal bleeding with, 527
- Placentation
in multiple gestation
outcomes and, 564
types of, 564
sonographic determination of, 564
- Platelet count, fetal, determination of, 436
- Platelet transfusions, for idiopathic thrombocytopenic purpura in pregnancy, 436
- Pneumonia, neonatal, preterm premature rupture of membranes and, 461
- Polyhydramnios, in twin gestation, 37, 85, 105
- Polymorphonuclear leukocytes, in premature rupture of membranes, 810
- Positive predictive value, of diagnostic tests, calculation of, 267
- Postpartum complications, early postpartum discharge and, 611
- Potassium chloride, in management of ectopic pregnancy, 382
- Potter's syndrome (Potter's facies), 817, 870
- Practice guidelines
Agency for Health Care Policy and Research (AHCPR) perspective on, 343
American College of Obstetricians and Gynecologists (ACOG) perspective on, 343
American Medical Association (AMA) perspective on, 343
clarity of, 343
clinical applicability of, 343
clinical flexibility of, 343
definition of, 343
development of, 307, 343
documentation of, 343
evidence-based, 343
Institute of Medicine (IOM) perspective on, 343
multidisciplinary process and, 343
reliability/reproducibility of, 343
scheduled review and, 343
validity of, 343
- Prazosin
adverse effects and side effects of, 691
for voiding dysfunctions, 691
- Prenatal care, and diabetes mellitus, 584
- Prednisone
for asthma, in pregnancy, 555
for idiopathic thrombocytopenic purpura in pregnancy, 436
- Preeclampsia. See also Hypertension, gestational; Pregnancy-induced hypertension
ambulatory management of, 533
clinical features of, 533
definition of, 533
management of, 533
mild, definition of, 533
in multiple gestation, 564
outpatient management of, studies of, 533
peripheral manifestations of, 481
severe, diagnostic criteria for, 533
superimposed on chronic hypertension, definition of, 533
with twin gestation, 85
- Pregnancy
antihypertensive therapy in, studies of, 533
asthma in. See Asthma
bacteriuria in, 744
asymptomatic, 744
bleeding in
with abruptio placentae, 527
with placenta previa, 527
diabetes in. See Diabetes mellitus
diuretic therapy in, adverse effects of, 533
ectopic. See Ectopic pregnancy
healthcare interventions in, systematic reviews of, 315
high-risk
antepartum care setting for, selection of, 626
antepartum home care for, psychosocial effects of, 626
antepartum hospitalization for, psychosocial effects of, 626
childbirth education in, 626
definition of, 626
due to complications of pregnancy, 626
due to pre-existing chronic condition, 626
emotional responses to, 626
father's perspective on, 626
implications for health care professionals, 626
interventions in, and assessment of psychosocial impact of, 626
mismatched caring and, 626
outpatient management of, 481
patient information about, 626
psychosocial effects of, 626
recommendations for future research on, 626
resource books on, 626

- setting of care for, and emotional responses, 626
- stressors associated with, 626
- support groups and networks for, 626
- supportive care in, 626
- idiopathic thrombocytopenic purpura in, management of, 436
- insulin therapy in, 584
- nausea and vomiting in. *See* Nausea and vomiting outcome
 - with hypertension in pregnancy, 533
 - in perimenopausal woman, 958
- in perimenopause, 921, 951, 958, 976
- prolongation, antibiotic therapy for preterm premature rupture of membranes and, 461, 870
- screening during. U.S. Preventive Services Task Force recommendations on, 332
- thrombocytopenia in, causes of, 436
- thromboembolism in
 - anticoagulation for, 545
 - pathogenesis of, 545
 - prevention of, 545
- tubal. *See* Ectopic pregnancy
- ultrasound examinations during. U.S. Preventive Services Task Force recommendations on, 332
- urinary tract infections in, 744
- Pregnancy-induced hypertension. *See* also Antihypertensive therapy; Hypertension, gestational; Preeclampsia
 - outpatient management of, 481
 - studies of, 533
 - skilled nursing facility criteria for, 481
- Pregnancy loss
 - after first missed menses, 37
 - before first missed menses, 37
 - with multifetal pregnancy reduction, 47
 - in multiple gestation, 37, 127
 - in twin gestation, 37
 - after first missed menses, 37
 - etiologies, 37
 - before first missed menses, 37
 - prevention, 37
 - in second trimester, rate of, 37
 - and in singleton pregnancy, comparison, 37
- Premature rupture of membranes
 - definition of, 832
 - enzymatic activity and, 810
 - epidemiology of, 883
 - etiology of, 810, 883
 - expectant management versus delivery in, 883
 - fetal factors and, 810
 - and gestational age-dependent morbidity, 461, 827, 832
 - host factors and, 810
 - latency period with, 503, 817, 827, 832, 870
 - management of, 817, 870, 883
 - outcome with, 810
 - preterm. *See* Preterm premature rupture of membranes
 - prolonged, 817
 - clinical management of, 817
 - and deformities, 817
 - expectant management versus delivery in, 817
 - and fetal growth deficiency, 817
 - and Potter's facies, 817
 - and pulmonary hypoplasia, 817
 - risk factors for, 810, 883
 - skilled nursing facility criteria for, 481
 - in term patients, management of, 883
- Prematurity. *See* also Delivery, preterm; Labor, preterm; Spontaneous preterm birth
 - history-taking and, 491
 - incidence of, 491
 - postnatal complications of, 491
 - prevention of, 491
 - recurrence risk, 491
 - risk factors for, 491
 - risk of
 - cervical length and, 491
 - gestational age at prior preterm birth and, 491
- Premenstrual syndrome (PMS)
 - definition of, 405
 - interventions for
 - effective, 405
 - ineffective, 405
 - selection of, 405
 - that may be effective, 405
 - treatment of, 405
 - historical perspective on, 405
- Prenatal care
 - for patient at risk for spontaneous preterm birth, 491
 - for patient without risk of spontaneous preterm birth, 491
 - in twin gestation, 85
- Preterm birth
 - definition of, for twins versus singletons, 3
 - in multifetal gestation
 - fetal fibronectin and, 95
 - home monitoring devices for predicting, 95
 - with multifetal pregnancy reduction, 47
 - of multiples
 - population-based data on, 3
 - risk, population-based studies of, 3
 - population-based data on, 3
 - rate, in twins versus singletons, 13, 31
 - risk, among twins and triplets, 3
 - of twins
 - population-based data on, 3
 - prevention, 67, 95
 - rate, reduction, 13, 31, 95
 - risk, techniques for assessing, 95
- Preterm labor. *See* Labor, preterm
- Preterm premature rupture of membranes (pPROM)
 - after midtrimester, 827, 832
 - amniotic fluid assessment with, 832
 - antibiotic therapy for, 461, 832, 864, 870
 - and gestational age-dependent morbidity, 461, 827
 - literature on, 461
 - maternal outcome with, 461, 827
 - NICHD-MFMU multicenter trial of, 461
 - and perinatal infectious morbidity, 461, 827
 - and perinatal mortality, 461, 827, 870
 - pregnancy prolongation with, 461
 - prospective trials of, 461, 864
 - rationale for, 864
 - regimen for, 461
 - cervical cerclage and, 503, 870
 - clinical implications of, 503
 - confirmation of membrane rupture in, 870
 - corticosteroid therapy with, 461, 503, 564, 832, 842, 870

- definition of, 503
- diagnosis of, 503
- differential diagnosis of, 870
- etiology of, 503
- and gestational age-dependent morbidity, 461, 827, 832, 870
- and herpetic lesions, 503
- home management of, 481, 503, 870
- infectious complications of, 503, 827
- initial evaluation of, 503
- inpatient management of, 481
- latency period with, 503, 827, 832, 870
- long-term outcome in child after, 827
- management of, 461, 832, 870
 - active, 842
 - conservative
 - versus expeditious, 832, 870
 - treatment during, 832, 870
 - evaluation of fetal well-being in, 870
 - historical perspective on, 503
 - initial, 870
 - initial approach to, 832
 - subsequent to limit of fetal viability, 870
 - traditional approach to, 842
- monitoring of patients with, recommendations for, 849
- neonatal consequences of, 827, 832, 870
- outcome with, 810, 870
- and perinatal infectious morbidity, 461, 827, 832
- and perinatal mortality, 461, 827, 832, 870
- prevalence of, 503, 810, 827, 832
- previable/midtrimester, 827, 832, 870
- risk factors for, 491
- tocolytic therapy with, 461, 842, 870
 - contraindications to, 503, 842
 - controlled trials of, 842
 - efficacy of, 842
 - gestational age and, 842
 - potential interaction with corticosteroid treatment, 842
 - potential risks of, 503
 - prophylactic, 842
 - success of, factors affecting, 842
 - theoretical benefits of, 842
- ultrasound in, 870
- Prevalence studies. See Cross-sectional studies
- Preventive services
 - for average risk women, U.S. Preventive Services Task Force recommendations on, 332
 - controversies concerning, 332
 - delivery of, in primary care setting, U.S. Preventive Services Task Force conclusions on, 332
 - U.S. Preventive Services Task Force recommendations on, 332
- Pro-Banthine. See Propantheline bromide
- Procardia. See Nifedipine
- Prochlorperazine, for hyperemesis gravidarum, 597
- Proctalgia fugax, 422
- Progesterone
 - and age-related ovarian changes, 898
 - levels, age-related changes in, 913
 - for premenstrual syndrome, ineffectiveness of, 405
- Progestins
 - ovulation suppression by, for premenstrual syndrome, effectiveness of, 405
 - and prevention of preterm delivery in twin gestation, 13
 - for women with dysfunctional uterine bleeding, 928
- Prognosis, definition of, 235
- Progressive retroperitoneal fibrosis, chronic pelvic pain with, 422
- Proliferation index, of luteinized granulosa cells, age-related changes in, 898
- PROM. See Premature rupture of membranes
- Promethazine, for hyperemesis gravidarum, 597
- Propantheline bromide, for urinary incontinence, 691
- Prostaglandin $F_{2\alpha}$, in management of ectopic pregnancy, 382
- Prostaglandins
 - for cervical ripening, 606
 - for urinary incontinence, 691
- Prostate, Lung, Colorectal, and Ovary (PLCO) Trial, 200
- Protamine sulfate, 545
- Protein C. See also Activated protein C resistance deficiency, anticoagulation for, 545
- Protein S, deficiency, anticoagulation for, 545
- Proteinuria, definition of, 533
- Proteus, urinary tract infection caused by, 744
- Pseudomonas, urinary tract infection caused by, 744
- Psychotherapy
 - focused, for chronic pelvic pain patient, 422
 - for premenstrual syndrome, possible effectiveness of, 405
 - for urinary incontinence, 702
- Psychotropic medications, for chronic pelvic pain, 422
- Psyllium mucilloid (Metamucil, Equate), 422
- Pulmonary edema, maternal, in multiple gestation, 564
- Pulmonary embolism
 - morbidity and mortality with, 545
 - prevention of, 545
 - treatment of, 545
- Pulmonary hypoplasia
 - incidence of, 817
 - neonatal, with preterm premature rupture of membranes, 503, 827, 870
 - in oligohydramnios tetrad, 817
 - pathophysiology of, 817
- P-value
 - definition of, 257
 - use of, 257
- Pyelonephritis
 - acute, 744
 - in pregnancy
 - diagnosis of, 515
 - laboratory findings in, 515
 - prevalence of, 515
 - and renal function, 515
 - risk factors for, 515
 - signs and symptoms of, 515
 - uropathogens for, 515
 - ambulatory management of
 - follow-up evaluation in, 515
 - in nonpregnant women, 515
 - patient education about, 515
 - in pregnant women, 515
 - recommendations for, 515
 - antibiotic therapy for, 515, 744
 - intramuscular, 515

- intravenous, 515
 - oral, 515
 - in pregnancy, 744
 - bacteremia with, 515, 744
 - blood culture in, 515
 - chronic, 744
 - in pregnancy, 515
 - complications of, 515
 - with diabetes in pregnancy, 584
 - histology of, 744
 - occult, definition of, 744
 - pathophysiology of, 744
 - in pregnancy
 - ambulatory management of, 515
 - hospitalization for, 515
 - management of, 481, 744
 - outpatient management of, 481
 - and premature delivery, 515, 744
 - and preterm labor, 515, 744
 - prevention, in pregnancy, incremental cost-effectiveness of, 296
 - recurrence, 515
 - prevention, with nitrofurantoin suppression, 515
 - signs and symptoms of, 744
 - treatment of
 - conventional regimens for, 515
 - in pregnancy, 744
 - urine culture in, 515
 - uropathogens in, 515, 744
- Pyridoxine**
- for hyperemesis gravidarum, 597
 - for premenstrual syndrome, ineffectiveness of, 405
- Q-tip test**, in patient with urinary incontinence, 663
- Quadruplet gestation**. See also Multiple gestation
- intrauterine growth in, relationship to birth weight and gestational age, 57
 - maternal weight gain with, 57
 - NICU admission rates with, 564
- Quality improvement programs**, 348
- Quality management**, in OB/GYN, evidence-based, 348
- Quality of adjusted life-year (QALY)**, 296
- Quality of care**
- in fee for service system, 481
 - managed care and, 481
 - in OB/GYN
 - ACOG measures for, 348
 - interventions to improve, examples of, 348
 - JCAHO measures for, 348
 - measurement, examples of, 348
 - overview of, 348
- Quinestradol**, for urinary incontinence, 691
- Quinolones**, for pyelonephritis, 515
- RADIUS study**, 67
- Randomization**. See also Clinical trials, randomized;
- Randomized controlled trials (RCTs)
 - advantages of, 245
 - allocation concealment in, 245
 - assignment in, systematic methods of, 245
 - assignment sequence for
 - concealment of, 245
 - deciphering of, personal accounts of, 245
 - generation of, 245
 - balanced (restricted), 245
 - blinding (masking) measures in, 245, 307
 - definition of, 245
 - evaluation of, 307
 - implementation of, 245
 - principles and rationale for, 245
 - processes of, 245
 - recommendations on, 245
 - simple (unrestricted), 245
 - violations of, 245
 - without foreknowledge, 245
- Randomized controlled trials (RCTs)**, 245. See also Randomization
- bias in, prevention of, 245
 - of electronic fetal monitoring, in meta-analysis, 275, 362
 - evaluation of, 307
 - handling of, in meta-analysis, 275, 362
 - historical perspective on, 245
 - reporting of, 245
 - Consolidated Standards of Reporting Trials (CONSORT) and, 245
- Recall bias**, in case-control studies, 307
- Receiver operating characteristic (ROC) curves**, use of, 267
- Records release form**, 657
- Rectocele**
- and enterocele, differentiation of, 663
 - identification of, 663
 - surgical management of, 786
- Reflex sympathetic dystrophy**, chronic pelvic pain with, 422
- Reglan**. See Metoclopramide
- Relative risk (RR)**, 235
- Relaxin**, for cervical ripening, 606
- Reproductive aging**. See also Follicular atresia; Menopause; Perimenopause
- and fertility, 913
 - physiology of, 913
- Research studies**. See also Observational studies
- attrition, and sample size determination, 257
 - design of, 235. See also Randomization
 - suggested further reading on, 257
 - dropout from, and sample size determination, 257
 - evaluation of, 307
 - potential complications in, 257
 - principles and rationale for, 235
- Residual ovary syndrome**, 215
- Respiratory distress syndrome**. See also Adult respiratory distress syndrome
- neonatal, preterm premature rupture of membranes and, 461, 827, 832
 - prevention of, 564, 832
- Retinoblastoma**, 172
- Retropubic colpourethropey**, 786
- Retropubic urethropey**, 712, 786
- Ripstein procedure**, for rectal prolapse, 786
- Risk assessment**, in perimenopausal woman, 966
- Risk ratio**, 235
- Robinul**. See Glycopyrrolate
- ROC curves**. See Receiver operating characteristic (ROC) curves
- Routine antenatal diagnostic imaging ultrasound (RA-DIUS) study**, 67
- RU 486**. See Mifepristone
- Rupture of membranes**. See also Premature rupture of

- membranes; Preterm premature rupture of membranes
 - causes of, infectious versus noninfectious, 832
 - and gestational age-dependent morbidity, 461, 827, 832, 870
 - latency after, 832
- Sacrospinous vault suspension, prophylactic, 786
- Salivary estriol test, and risk of preterm delivery, 491
- Sample size (n), 257
 - calculation of, 257
 - for comparing mean postoperative pain levels, 257
 - for comparing medians, 257
 - for comparing proportions, 257
 - examples of, 257
 - guidelines for, 257
 - for multigroup comparisons, 257
 - for observational studies, 257
 - potential complications in, 257
 - for repeated measures studies, 257
 - software for, 257
 - evaluation of, 307
 - study design and, 257
- Screening
 - for breast cancer, U.S. Preventive Services Task Force recommendations on, 332
 - definition of, 267
 - for gestational diabetes, U.S. Preventive Services Task Force recommendations on, 332
 - for ovarian cancer, U.S. Preventive Services Task Force recommendations on, 332
 - in pregnancy, U.S. Preventive Services Task Force recommendations on, 332
- Screening tests
 - and diagnostic tests, comparison of, 267
 - evaluation of, study design for, 267
 - features of, 267
 - U.S. Preventive Services Task Force recommendations on, 332
 - use of, 267
- Selective follicular reduction, 127
- Selective serotonin reuptake inhibitors (SSRIs)
 - adverse effects and side effects of, 405
 - for premenstrual syndrome, effectiveness of, 405
- Selective termination
 - and multifetal pregnancy reduction, comparison of, 47
 - in twin pregnancy, 67
- Self-catheterization (clean, intermittent)
 - advantages and disadvantages of, 735
 - in postoperative bladder drainage, 735
 - technique for, preoperative teaching of, 735
- Sensitivity, of diagnostic tests, 267
- Sensitivity analysis, 296
 - multi-way, 282
 - one-way, 282
 - three-way, 282
 - two-way, 282
- Sepsis
 - neonatal, and early postpartum discharge, 611
 - preterm premature rupture of membranes and, 461, 827
- Septic shock, with pyelonephritis in pregnancy, 515
- Sertraline, for premenstrual syndrome, effectiveness of, 405
- Sexual abuse, childhood, and chronic pelvic pain, 422
- Sexual function, in perimenopause, 921, 976
- Significance level (α), 257
- Simethicone (Mylicon), 422
- Sinequan. See Doxepin
- Skilled nursing facility, criteria for obstetrically related conditions, 481
- Sleep disturbances, in perimenopause, 921, 976
- Smoking
 - and contraception, 958
 - and premature rupture of membranes, 810
- Somatization, with hyperemesis gravidarum, 597
- Specificity, of diagnostic tests, 267
- Spina bifida
 - embryology of, 393
 - neonatal therapy for, 393
 - prognosis for, 393
 - prophylactic cesarean delivery for, 393
- Spirolactone, for premenstrual syndrome, possible effectiveness of, 405
- Splenectomy, for idiopathic thrombocytopenic purpura in pregnancy, 436
- Spontaneous preterm birth
 - epidemiology of, 491
 - history-taking and, 491
 - prenatal care for patient at risk for, 491
 - recurrence risk, 491
 - risk factors for, 491
 - nonrecurrent, 491
 - recurrent/immutable, 491
 - recurrent/treatable, 491
 - risk of
 - cervical length and, 491
 - gestational age at prior preterm birth and, 491
 - risk scoring systems for, 491
- SPTB. See Spontaneous preterm birth
- Standards of quality, definition of, 343
- Staphylococcus, coagulase-negative, urinary tract infection caused by, 744
- Staphylococcus saprophyticus, urinary tract infection caused by, 744
- Statistical power (1- β), 257
 - definition of, 257
 - retrospective calculation of, 257
- Statistics, basic terminology for, 257
- Statistics, 2nd Edition (Freedman et al.), 257
- Sterilization, of women, rates by age, 951
- Steroids. See also Corticosteroids
 - adverse effects and side effects of
 - fetal effects of, 436
 - maternal, in pregnancy, 436
 - antenatal
 - in multiple gestation, 564
 - preterm premature rupture of membranes and, 832
- STOP-DUB. See Surgical Treatment Outcomes Project for Dysfunctional Uterine Bleeding
- Streptococcus, group B
 - early-onset neonatal infection, prevention, 870
 - clinical decision analysis for, 282
- sepsis, antibiotic therapy for preterm premature rupture of membranes and, 461, 870
- Stress management, for premenstrual syndrome, possible effectiveness of, 405
- Stress urinary incontinence. See Urinary incontinence, stress/genuine stress

- Stroke
 oral contraceptives and, 951
 risk factors for, 951
- Stuck twin (syndrome), 105, 564
- SUI. See Urinary incontinence, stress/genuine stress
- Sulprostone, in management of ectopic pregnancy, 382
- Superovulation, 127
 gonadotropin-stimulated, alternatives to, 127
- Suprapubic catheter
 advantages and disadvantages of, 735
 contraindications to, 735
 indications for, 735
 placement technique for, 735
 in postoperative bladder drainage, 735
 advantages of, 735
- Surgery, prophylactic, and familial cancer risk reduction, 215
- Surgical Treatment Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB), 257
 Systemic lupus erythematosus, chronic pelvic pain with, 422
- Tachysystole, of fetal heart rate, cervical ripening and, 606
- Tamoxifen, and cancer risk reduction, 200
- Telephone contact, in obstetrics/gynecology, 640
 breach of confidentiality and, 640
 failure to diagnose and, 640
 failure to follow up and, 640
 improper treatment and, 640
 inadequate documentation and, 640
 interviewing techniques for, 640
 liability claims with, 640
 liability risks with, 640
 reduction of, 640
 and non-English-speaking callers, 640
 patient's primary problem in, 640
 as percentage of patient encounters, 640
 physician action in response to, 640
 poor telephone procedures and, 640
 quality of care and, 640
 telephone manners for, 640
 treatment delay and, 640
- Teloscopy, intraoperative, 755
- Terazosin chloride, for voiding dysfunctions, 691
- Terbutaline, for asthma, in pregnancy, 555
- Terodiline hydrochloride, for urinary incontinence, 691
- Test statistic, definition of, 257
- Theophylline, for asthma, in pregnancy, 555
- Thiamine, replacement, with hyperemesis gravidarum, 597
- Thiazide diuretics, in pregnancy, adverse effects of, 533
- Threshold analysis, 296
- Thrombocytopenia
 fetal, 436
 heparin-induced, 545
 with hypertension in pregnancy, 533
 in pregnancy, causes of, 436
- Thromboembolism
 in pregnancy or puerperium
 anticoagulation for, 545
 outpatient management of patient at risk for, 545
 pathogenesis of, 545
 prevention of, 545
 treatment of, 545
 venous, anticoagulation for, 545
- Thyroid cancer, medullary, 172
- Tocolysis
 in management of preterm premature rupture of membranes, 461, 842, 870
 contraindications to, 503, 842
 controlled trials of, 842
 efficacy of, 842
 gestational age and, 842
 potential interaction with corticosteroid treatment, 842
 potential risks of, 842
 prophylactic, 842
 success of, factors affecting, 842
 theoretical benefits of, 842
 therapeutic, 842
 in multiple gestation, 564
 in preterm labor, 491
- Tocopherol, for premenstrual syndrome, ineffectiveness of, 405
- Tofranil. See Imipramine hydrochloride
- Tolterodine, for urinary incontinence, 691
- Tranexamic acid, for women with dysfunctional uterine bleeding, 928
- Transcutaneous electrical nerve stimulation, and uterine contraction, 606
- Transfusion, postpartum, with trial of labor after cesarean delivery, 369
- Trial of labor, after cesarean delivery, 369
 breech presentation and, 369
 candidates for, 369
 decision to proceed with, factors affecting, 369
 evaluation of literature on, evidence-based approach to, 369
 fetal macrosomia and, 369
 induction of labor and, 369
 maternal morbidity with, 369
 maternal mortality with, 369
 multiple gestation and, 369
 perinatal morbidity and mortality with, 369
 success of, prediction of, 369
 success rate for, 369
- Tricyclic drugs (tricyclic antidepressants)
 adverse effects and side effects of, 691
 for chronic pelvic pain, 422
 for urinary incontinence, 691
- Trigger points, and chronic pelvic pain, 422
 diagnosis of, 422
- Trimethobenzamide, for hyperemesis gravidarum, 597
- Trimethoprim-sulfamethoxazole, for pyelonephritis, 515
- Triptelennamine, for asthma, in pregnancy, 555
- Triplet births
 cesarean delivery for
 clinical evidence for, 25
 theoretical arguments for, 25
 delivery route for, 25
 NICU admission rates with, 564
 preterm, risk, 3
 vaginal delivery for
 clinical evidence for, 25
 theoretical arguments for, 25
- The Triplet Connection, 85, 127
- Triplet gestation. See also Multiple gestation
 fetal/intrauterine growth in
 patterns, in United States, 115

- relationship to birth weight and gestational age, 57, 115
- maternal age and, 3
- maternal weight gain with, 57
- perinatal mortality with, 57
- Triploidy, hyperemesis gravidarum with, 597
- Trisomy 21
 - hyperemesis gravidarum with, 597
 - prenatal diagnosis of, 564
- Trypsin, and premature rupture of membranes, 810
- t statistic, 257
- Tubal ligation, and ovarian cancer risk reduction, 200
- Tubal pregnancy. See Ectopic pregnancy
- Tumor suppressor gene, p53
 - in cancer susceptibility, 172
 - discovery of, 172
 - expression, regulation, 172
 - functions of, 172
 - gene therapy for, 172
 - germline mutations, and familial cancer susceptibility syndromes, 172
 - and gynecologic cancer, 172
 - inactivation, 172
 - mutant, treatment approaches to, 172
 - mutations, detection of, 172
 - as transcriptional regulator, 172
- Turcot's syndrome, 172
- Twin births
 - data sets on, 3
 - delivery, at Level III hospital, 85
 - delivery route for, 31
 - with nonvertex/nonvertex fetal presentation, 31
 - with nonvertex/vertex fetal presentation, 31
 - with vertex/nonvertex fetal presentation, 31
 - with vertex/vertex fetal presentation, 31
 - postpartum complications, anticipatory management of, 85
 - preterm
 - definition of, 3
 - rate, reduction, 13, 31
 - risk, 3, 31
- Twin Clinic, 13, 67, 85, 105
- Twinning/twin gestation. See also Multiple gestation
 - acardiac, 564
 - amnionicity, determination, 67, 85
 - anemia with, 85
 - chorionicity, determination, 67, 85
 - complications of, anticipatory management of, 85
 - demographic variables related to, 3, 79
 - diagnosis, 67, 85
 - dizygotic, 564
 - congenital anomalies in, 564
 - fetal death with, 564
 - fetal/intrauterine growth in
 - discordant, 57, 67, 85, 105
 - measurement of, 85
 - patterns, in United States, 115
 - relationship to birth weight and gestational age, 57, 115
 - fetal lung maturation in, 564
 - incidence of, 564
 - intertwin vascular connections in, 105
 - intrauterine growth restriction with, 564
 - maternal age and, 3
 - maternal weight gain with, 57
 - monochorionic
 - complications, 105
 - and dichorionic, comparison, 105
 - frequency, 105
 - morbidity and mortality with, 105
 - monozygotic, 564
 - congenital anomalies in, 564
 - dichorionic-diamniotic, 564
 - and dizygotic, comparison, 85, 105
 - incidence of, assisted reproductive technology and, 127
 - monochorionic-diamniotic, 564
 - monochorionic-monoamniotic, 564
 - neonatal death with, 564
 - optimal length of gestation for, 31
 - outcomes with, 564
 - parents
 - preparation of, 85
 - self-help groups for, 85
 - perinatal mortality with, 57, 564
 - by gestational age, 3
 - preeclampsia with, 85
 - pregnancy loss in, 37
 - after first missed menses, 37
 - etiologies, 37
 - before first missed menses, 37
 - prevention, 37
 - in second trimester, rate of, 37
 - and in singleton pregnancy, comparison, 37
 - prenatal care in, 85
 - preterm labor with, prevention, 13
 - rates, by zygosity, 564
 - recognition of
 - early, benefits, 67
 - early versus late, 85
 - risks of, anticipatory management of, 85
 - selective fetal reduction in, 67, 564
 - single fetal demise in, management of, 564
 - sonographic examination in, 564
 - ultrasound in, controlled trials of, 67
 - vanishing fetus in, 564
 - zygosity in, 85, 105
- Twin peak, with dichorionic placentas, 67
- Twin reversed arterial perfusion (TRAP), 105
- Twins, conjoined
 - embryology of, 564
 - incidence of, 564
- Twin-twin transfusion syndrome (TTS), 37, 105, 564
 - acute perinatal, 105
 - antenatal
 - diagnosis, 85, 105
 - pathophysiology, 85, 105
 - therapy for, 85, 105
 - diagnosis, 67, 85
 - and neonatal mortality, 57
- Two by two table, 235, 267
- Type I error, 257
- Type II error, 257
- Ultrasound
 - with abruptio placentae, 527
 - of cervix
 - and digital evaluation, comparison, 95
 - findings in, and risk of preterm delivery, 491
 - in detection of placenta previa, 527

- in determination of chorionicity, 67, 85
- in diagnosis and management of congenital anomalies, 67
- fetal growth assessment using, 67
- fetal well-being assessment using, 67
- in multiple gestation, 564
- during pregnancy, U.S. Preventive Services Task Force recommendations on, 332
- with premature rupture of membranes, 817, 870
- and prevention of prematurity, 67
- with rupture of membranes, 503
- transvaginal
 - for cervical length measurements, 95
 - of cervix, in pregnancy, 491
 - for detection of ovarian cancer, 200, 215
 - in patient with abnormal uterine bleeding, 928
- twin peak sign (lambda sign) in, 564
- in twin pregnancy
 - controlled trials of, 67
 - and early recognition of twinning, 67, 85
- universal, in pregnancy
 - controversy about, in United States, 67
 - denial of access to, ethical considerations, 67
- urologic, in pregnancy, 515
- Umbilical artery, systolic-to-diastolic blood flow (S/D) ratio, and intrauterine infection with preterm premature rupture of membranes, 849
- Umbilical cord
 - compression, with preterm premature rupture of membranes, 870
 - prolapse, with preterm premature rupture of membranes, 503, 827
- Urecholine, for urinary incontinence, 691
- Ureter
 - abnormalities of, on cystourethroscopy, 764
 - anatomy of, normal, 755
 - functions of, normal, 755
 - injury and repair of, 755
 - intraoperative evaluation of, 755
- Ureteral catheter, intraoperative, 755
- Ureteral duplication, 764
- Ureterocele, 764
- Urethra
 - anatomic support of, and urinary continence, 719
 - anatomy of, normal, 755
 - carcinoma, 764
 - changes during stress, and urinary continence, 719
 - coaptation and closure of, and urinary continence, 719
 - condylomata, 764
 - diverticula, 764
 - fronds, 764
 - functions of, normal, 755
 - hypermobile, 712, 719, 777
 - with normal function, and surgical management of urinary incontinence, 712
 - with poor function, and surgical management of urinary incontinence, 712
 - Q-tip test for, 663
 - kinking or blockage, by prolapsed pelvic organ, 777
 - length of
 - anatomic, 672, 719
 - functional, 672, 719
 - and urinary continence, 719
 - luminal dilation, assessment of, 777
 - neurophysiology of, 691
 - nonmobile, surgical management of urinary incontinence with, 712
 - pathology of, on cystourethroscopy, 764
 - position of, and urinary continence, 719
 - proximal, scarring of, 764
 - sphincter function, assessment of, 712
- Urethral insert, in management of urinary incontinence, 702
- Urethral patch, 702
- Urethral pressure
 - maximum, 672
 - maximum urethral closure pressure, 672
 - mean urethral closure pressure, 672
- Urethral pressure profilometry, 672
 - clinical applications of, 672
 - parameters in, 672
- Urethral syndrome, 764
- Urethritis
 - atrophic, 764
 - chronic, chronic pelvic pain with, 422
 - clinical features of, 744
 - microbiology of, 744
- Urgency
 - definition of, 691
 - disorders associated with, 691
 - motor, 691
 - sensory, 691
- Urinary continence
 - mechanisms of, 719
 - UCLA theory of, 719
- Urinary incontinence
 - alpha adrenergic agents for, 691, 702
 - anticholinergic agents for, 691
 - anticholinergic antispasmodic agents for, 691
 - behavior therapy for, 702
 - calcium channel blockers for, 691
 - depression and, 663
 - differential diagnosis of, 672
 - drug history with, 663
 - estrogen therapy for, 691, 702
 - etiology of
 - genitourinary, 672
 - nongenitourinary, 672
 - general appearance of patient with, 663
 - general examination of patient with, 663
 - hypertension and, 663
 - indications for referral to urogynecology subspecialist, 672
 - leak point pressure studies in, 672
 - Marshall-Bonney test for, 663
 - mechanical devices in management of, 702
 - mixed, 672
 - nonsurgical therapies for, 702
 - pelvic floor muscle strengthening in, 702
 - obesity and, 663
 - pad testing for, 663
 - pelvic examination in patient with, 663
 - with pelvic prolapse, 777
 - evaluation of patient with, 777
 - surgical management of, 777
 - pharmacologic therapy for, 691, 702
 - to decrease bladder contractility, 691
 - to decrease urethral resistance, 691
 - to facilitate bladder emptying (voiding phase), 691
 - to facilitate bladder storage (filling phase), 691

- to increase bladder contractility, 691
- to increase urethral outlet resistance, 691
- physical examination of patient with, 663, 712
- psychotherapy for, 702
- Q-tip test in patient with, 663
- stress/genuine stress, 672
 - after surgical repair of prolapsed pelvic organs, 777
 - diagnosis of, 712
 - Kegel exercises for, 702
 - pelvic organ prolapse with, 712
 - surgical management of, 712, 719, 786
- stress test in, 663
- surgical management of, 712, 777, 786
 - failure of, factors contributing to, 719
 - fistula after, 719
 - functional failure of, 719
 - with hypermobile urethra and normal urethral function, 712
 - with hypermobile urethra and poor urethral function, 712
 - intrinsic sphincteric deficiency and, 719
 - new onset bladder instability and urgency incontinence after, 719
 - with nonmobile urethra, 712
 - patient selection for, 719
 - and pelvic organ prolapse, 712
 - persistent incontinence after, 719
 - and postoperative urinary drainage, 735
 - procedure selection for, 712, 719
 - successful, characteristics of, 719
 - success in, factors affecting, 719
 - suture detachment/breakage and, 719
 - suture placement in, 719
 - technical failure in, 719
 - types of procedures for, 712, 719
 - unsuccessful, characteristics of, 719
 - urethrolisis in, 719
 - urinary obstruction after, 719
 - urinary tract injury in, prevention and management of, 755
- tricyclic drugs (tricyclic antidepressants) for, 691
- urethral pressure profilometry in, 672
- urge, 672
 - definition of, 691
 - preoperative diagnosis of, 777
- urodynamic evaluation for, 672. *See also* Urodynamic testing
- urologically oriented neurologic examination in, 663
- Urinary tract
 - anatomy of, normal, 755
 - functions of, normal, 755
 - injury, intraoperative, 755
 - intraoperative evaluation of, 755
 - preoperative evaluation of, 755
- Urinary tract infections
 - antibiotic therapy for, 744
 - catheter-associated, 744
 - complicated, definition of, 744
 - contraception and, 744
 - costs of, 744
 - definition of, 744
 - diagnosis of, 744
 - microbiology of, 744
 - in pregnancy, 744
 - prevalence of, 744
 - recurrence rate, 744
 - treatment of, 744
 - uncomplicated, definition of, 744
 - uropathogens in, 515, 744
- Urine volume
 - normal female, 672
 - postvoid residual, measurement of, 672
- Urispas. *See* Flavoxate hydrochloride
- Urodynamic testing, 777. *See also* Cystometry; Uroflowmetry
 - controversy about, 672
 - in evaluation of female urinary incontinence, 672
 - goals of, 672
 - leak point pressure studies in, 672
 - with pelvic prolapse, 672
 - pressure-flow studies in, 672
 - urethral pressure profilometry in, 672
- Uroflowmetry
 - abnormalities on, 672
 - clinical applications in women, 672
 - equipment for, 672
 - normal findings in, 672
 - principles and rationale for, 672
 - in urodynamic testing, 672
- Urogynecology, 656
- Urologic disorders, chronic pelvic pain with, 422
- U.S. Preventive Services Task Force
 - evidence-based medicine and, 332
 - evidence review and rating method, 307, 332
 - Guide to Clinical Preventive Services, 332
 - historical perspective on, 332
 - methodology of, 332
 - recommendations
 - for average risk women, 332
 - for counseling and chemoprophylaxis, 332
 - examples of, 332
 - on preventive services, 332
 - on screening tests, 332
 - strength of (classes A-E), 332
- Uterine activity, self-palpation of, in multifetal gestation, 95
- Uterine cervix. *See* Cervix
- Uterine rupture
 - clinical features of, 369
 - with trial of labor after cesarean delivery, 369
- Vaginal birth after cesarean delivery (VBAC), 348, 369
 - in twin gestation, 31
- Vaginal cancer, p53 tumor suppressor gene and, 172
- Vaginal cones, for pelvic floor muscle strengthening, 702
- Vaginal delivery
 - effects of epidural analgesia on, 449
 - for triplets and higher order multiples, 25
 - for twins, 31
- Vaginal fluid, nitrazine test of, with rupture of membranes, 503
- Vaginal vault prolapse, posthysterectomy, 786
- Vaginitis
 - clinical features of, 744
 - diagnosis of, 744
- Valium. *See* Diazepam
- Vanishing fetus, in twinning, 564

- Vanishing twin phenomenon, 37, 127
- Varicella Zoster Immune Globulin (VZIG), for pregnant women, cost-effectiveness analysis of, 296
- Vascular endothelial growth factor, and age-related ovarian changes, 898
- Vasomotor instability, in perimenopause, 921, 951, 966, 976
- Venous thromboembolism, anticoagulation for, 545
- Ventral wall defects, prenatally diagnosed, prophylactic cesarean delivery for, 393
- Vitamin B₆. See Pyridoxine
- Vitamin E. See Tocopherol
- Voiding
 - dysfunction
 - indications for referral to urogynecology subspecialist, 672
 - pharmacologic therapy for, 691
 - urodynamic evaluation of, 672
 - habit retraining for, 702
 - prompted, 702
 - timed, 702
- von Hippel-Lindau syndrome, 172
- Vulvar cancer, p53 tumor suppressor gene and, 172
- Vulvovaginal changes, in perimenopause, 921, 976
- Warfarin, therapeutic anticoagulation with, postpartum, 545
- Weight gain during pregnancy
 - and fetal growth of twins, 57
 - with multiple gestation
 - and fetal growth, 57
 - recommended versus actual, 57
 - and prevention of preterm delivery in twin gestation, 13
- Wernicke's encephalopathy, with hyperemesis gravidarum, 597
- West Haven-Yale Multidimensional Pain Inventory, 422
- White blood cell count, maternal, in diagnosis of intrauterine infection with PPROM, 849
- Wilms tumor, 172
- Work leave, and prevention of preterm delivery in twin gestation, 13
- Wound infection, with trial of labor after cesarean delivery, 369
- Xanax. See Alprazolam
- Zygosity
 - and neonatal mortality with multiple gestation, 57
 - in twin gestation, 85, 105

Author

Index

- Akashi, Makoto, 172
Alexander, Greg R., 115
Allen, Steven R., 842
Alnaif, Bunan, 786
Amuzu, Betty J., 702
Ancel, Pierre-Yves, 79
Atkins, David, 332
Ballard, David J., 348
Baron, Felice, 527
Bartfield, Michael C., 503
Becker, Jill, 735
Benachi, Alexandra, 31
Berchuck, Andrew, 157
Boardman, Lori A., 267
Bobrowski, Renee A., 545
Bopp, Bradford L., 898
Bouvier-Colle, Marie-Helene, 79
Brady, Kim, 810
Bréart, Gerard, 79
Brown, Haywood L., 545
Brubaker, Linda, 657
Brumfield, Cynthia G., 611
Carlan, S. J., 503
Carney, Michael, 157
Cervantes, Arturo, 13
Chasen, Stephen T., 67
Chen, Bruce, 832
Chen, Lee-May, 200
Chervenak, Frank A., 67
Chez, Ronald A., 606
Clark, Steven L., 555
Cohen, Arnold W., 481
Cohen, Matthew A., 958
Dickersin, Kay, 315
Dolan, Mary S., 348
Dolan, Mary Segars, 233, 307
Dommergues, Marc, 25
Drugan, Arie, 47
Drutz, Harold P., 786
Duff, Patrick, 809, 883
Dumez, Yves, 25
Ernest, J. M., 827
Esplin, M. Sean, 555
Evans, Mark I., 47
Faro, Sebastian, 744
Fenner, Dee E., 744
Futreal, Andrew P., 157
Gall, Stanley A., 564
Gardner, Michael, 296
Ginsberg, David A., 719
Goodwin, T. Murphy, 597
Greig, Phillip C., 849
Grimes, David A., 332
Grobman, William A., 37
Grody, Marvin H. Terry, 777
Heaman, Maureen, 626
Hecht, Bryan R., 127
Hill, Washington Clark, 479, 527
Hogan, Joseph W., 257
Homko, Carol J., 584
Iams, Jay D., 491
Johnson, Mark P., 47
Johnson, Susan R., 405
Julian, Thomas M., 656, 663
Karlan, Beth Y., 140, 200
Karram, Mickey M., 672
Keith, Louis, 1, 13, 85
Keith, Louis G., 105
Kiely, John L., 3
Klein, Nancy A., 912
Koeffler, H. Phillip, 172
Kogan, Michael, 115
Kohli, Neeraj, 672
Kramer, Ralph L., 47
Kulak, Jaime, Jr., 976
Lancaster, Jonathan M., 157
Lipscomb, Gary H., 691
Lobo, Rogerio A., 894, 895
Locksmith, Gregory J., 864
Luke, Barbara, 57
Luthi, Jean-Christophe, 348
Machin, Geoffrey A., 105
Magoon, Martha W., 127
Mahieu-Caputo, Dominique, 25
Manheimer, Eric, 315
March, Charles M., 928
Marks, Jeffrey, 157
Martin, Joyce, 115
McMahon, Michael J., 369
Mercer, Brian M., 461, 870
Miller, David A., 647
Morrison, John C., 95
Nachtigall, Lila E., 921
Namnoum, Anne Brawner, 382
Oleszczuk, Jaroslaw J., 13, 85
Owen, John, 282, 393
Papiernik, Emile, 1, 13, 85, 115
Peaceman, Alan M., 37
Peipert, Jeffrey F., 235, 257, 267
Peterson, Herbert B., 275, 362
Phelan, Jeffrey P., 640
Phipps, Maureen Glennon, 235

Piver, M. Steven, 215
 Polzin, William J., 810
 Pons, Jean-Claude, 31
 Portera, J. Christopher, 712
 Portera, S. Greg, 691
 Raffel, Leslie, 141
 Raz, Shlomo, 719
 Reddy, Sujatha, 387
 Reece, E. Albert, 584
 Reiter, Robert C., 422
 Richards, Douglas S., 817
 Roberts, William E., 95
 Rock, John A., 387
 Rouse, Dwight J., 233, 282
 Rovner, Eric S., 719
 Sandles, Lisa G., 167
 Sauer, Mark V., 958
 Schmidt-Saros, Cecilia, 940
 Schulz, Kenneth F., 245
 Seifer, David B., 898
 Senat, Marie-Victoire, 79

Shellhaas, Cynthia S., 491
 Sibai, Baha M., 533
 Silver, Robert M., 436
 Soules, Michael R., 912
 Stroup, Donna F., 275, 362
 Summitt, Robert L., Jr., 712
 Thacker, Stephen B., 275, 362
 Thorp, James A., 449
 Utrie, John W., Jr., 755
 Warren, Michelle P., 976
 Weinberger, Michael W., 764
 Westhoff, Carolyn, 951
 Wild, Robert A., 966
 Wing, Deborah A., 515
 Witlin, Andrea G., 533
 Wong, Cheung, 215
 Yancey, Michael K., 832
 Yaron, Yuval, 47
 Young, Stephen B., 735
 Zinberg, Stanley, 343

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970; Section 3685, Title 39 United States Code) Date of Filing—October 1, 1998. Title of Publication—CLINICAL OBSTETRICS AND GYNECOLOGY; Frequency of Issue—Quarterly; Annual Subscription Price—\$128.00; Location of Known Office of Publication—Lippincott Williams & Wilkins, 12107 Insurance Way, Hagerstown, MD 21740; Location of Headquarters or General Business Offices of the Publisher—227 East Washington Square, Philadelphia, PA 18706; Publisher—Lippincott Williams & Wilkins, 227 East Washington Square, Philadelphia, PA 18706; Editors—Roy M. Pitkin, MD, Professor, Dept. of OB/GYN, UCLA School of Medicine, 10833 Le Conte Ave., Los Angeles, CA 90095-1740, James R. Scott, MD, Professor, Department of OB/GYN, College of Medicine/University of Utah, Salt Lake City, UT 84132; Managing Editor—Peter T. Christy, Lippincott Williams & Wilkins, 227 East Washington Square, Philadelphia, PA 18706; Owner—Lippincott Williams & Wilkins, 227 East Washington Square, Philadelphia, PA 18706, a wholly owned subsidiary of Wolters-Kluwer Corp., 1185 Avenue of the Americas, New York City, New York 10036 (Stadouderskade 1, 1054 FS Amsterdam, The Netherlands); Known Bondholders, Mortgagees and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—none. A. Total no. copies printed (*net press run*), average 8,300; actual 7,900; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average, none, actual, none; 2. Mail subscriptions, average 6,677, actual 5,974; C. Total paid circulation, average 6,677, actual 5,974; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 69, actual 68; E. Free distribution outside the mail, average, none, actual, none; F. Total free distribution (*sum of D and E*), average, 69, actual, 68; G. Total distribution (*sum of C and F*), average, 6,746, actual, 6,042; H. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 1,554, actual 1,858, 2. Returns from news agents, none; G. Total (*sum of G, H1, and H2*), average 8,300, actual 7,900. I certify that the statements made by me above are correct and complete. Beverly V. Dietrich, *Circulation Director*.